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ABSTRACT 
 
Epithelial misplacement is a benign pathology of the intestines that mimics 
invasive carcinoma and leads to a high degree of diagnostic difficulty in the 
discrimination between the two by pathologists. Particular difficulties are 
associated with the diagnosis between the two, and currently a National Expert 
Board of specialist pathologists delivers a second opinion for equivocal cases 
referred from local Hospitals. Novel analysis techniques to assist the diagnosis 
of epithelial misplacement vs. Cancer would not only aid the Board in the 
diagnosis, but speed up time taken to diagnosis for future patient management, 
and therefore increase overall patient satisfaction. 
This research aims to define the use of high resolution spectroscopy in the 
colon and assess its use in analysis of formalin-fixed paraffin-embedded tissue 
that has been routinely processed by the pathology laboratory. It is predicted 
that it will be an accurate, rapid and non-destructive novel diagnostic technique, 
and particularly useful in difficult cases such as in the discrimination of epithelial 
misplacement from cancer, making it a useful addition to the diagnostic process 
to improve efficiency of the patient diagnostic and treatment pathway. 
65 colonic samples were analysed from a total of 58 patients diagnosed with 
various colonic pathologies and spectra measured in high resolution using the 
Agilent® 620 FTIR microscope coupled to a 670 Agilent spectrometer in 
transmission mode. Spectra were then fed into a specialist computer software 
programme, analysed using principal component-fed linear discriminant 
analysis model and tested with a leave one sample out cross validation method. 
The ‘Two Group’ Model defined the ability of the high resolution spectral 
analysis to discriminate between epithelial misplacement and cancer with a 
sensitivity of 74.6% and specificity of 82.3%. These results are excellent and 
have never been recorded previously in the literature. However, further 
research is required to assess its role in the discrimination of various other 
colonic pathologies, and the model needs independent testing with new cases 
of both epithelial misplacement and cancer to continue the assessment of the 
novel high resolution technique. 
Page | 4 
 
ACKNOWLEDGEMENTS 
 
I would like to thank my supervisors for their support and contributions to this 
work - Professor Nick Stone for his continued help, insights and experience; 
Professors Neil Shepherd and Hugh Barr for their unwavering enthusiasm and 
support for the project from the very beginning, Dr Catherine Kendall for her 
patience and kindness and Mr Tim Cook for enabling my time out of medical 
training. I am very grateful for all your help. I would particularly like to thank Dr 
Gavin Lloyd for his great patience and assistance over the course of both data 
acquisition and analysis, and to the Post-doctorates Dr Krupakar Nallala in 
Exeter and Dr Martin Isabelle in Gloucester, without whom I would have been 
lost in a sea of a million spectra. So many thanks to you all. 
 
I am very grateful to Gloucestershire Hospitals NHS Foundation Trust for 
facilitating my research and to the team at the Gloucestershire Cellular 
Pathology Laboratory, Cheltenham for their assistance in the first few months of 
the project. 
 
Finally, to my husband and son who have been a great source of love and 
support over the past year, and daughter who arrived to cheerlead the writing 
up, thank you all. 
 
 
 
  
Page | 5 
 
CONTENTS 
ABSTRACT .................................................................................................................. 3 
ACKNOWLEDGEMENTS ............................................................................................. 4 
LIST OF ABBREVIATIONS ........................................................................................... 8 
LIST OF FIGURES ....................................................................................................... 9 
LIST OF TABLES ....................................................................................................... 13 
LIST OF APPENDIX A FIGURES ............................................................................... 14 
CHAPTER 1 ............................................................................................................... 15 
THE COLORECTUM AND COLORECTAL CANCER ............................................. 15 
1.1 The Colon and Rectum .......................................................................................... 15 
1.1.1 Anatomy ............................................................................................................. 15 
1.1.2 Blood supply ....................................................................................................... 16 
1.1.3 Histology ............................................................................................................. 17 
1.2 Colorectal cancer in the UK ................................................................................... 19 
1.3 National Bowel Cancer Screening .......................................................................... 20 
1.3.1 The National Bowel Cancer Screening Programme ............................................ 21 
1.4 Management of Colorectal Cancer ......................................................................... 23 
1.4.1 Management of Early Polyp cancers ................................................................... 25 
1.5 Colorectal cancer ................................................................................................... 26 
1.5.1 Pathogenesis of Colorectal Cancer ..................................................................... 27 
1.6 Colorectal polyps ................................................................................................... 29 
1.6.1 Hyperplastic and other serrated polyps: .............................................................. 30 
1.6.2 Adenomatous polyp: ........................................................................................... 30 
1.6.3 Mixed polyps: ...................................................................................................... 32 
1.6.4 Carcinomatous Polyps: ....................................................................................... 32 
1.7 Epithelial Misplacement ......................................................................................... 34 
1.7.1 Epithelial Misplacement in colonic polyps: .......................................................... 35 
1.8 Clinical Diagnostic Need ........................................................................................ 36 
CHAPTER 2 ............................................................................................................... 38 
VIBRATIONAL SPECTROSCOPY .......................................................................... 38 
2.1 Biophotonics .......................................................................................................... 38 
2.2 What is light? ......................................................................................................... 38 
2.3 Biological Diagnostics ............................................................................................ 41 
2.4 Overview of Wide-field Imaging Techniques .......................................................... 43 
2.4.1 High definition white light endoscopy .................................................................. 43 
2.4.2 Chromo-endoscopy ............................................................................................. 43 
Page | 6 
 
2.4.3 Virtual Chromo-endoscopy .................................................................................. 44 
2.4.4 Fluorescence spectroscopy ................................................................................ 45 
2.5 Point Measurement Techniques............................................................................. 46 
2.5.1 Confocal Fluorescence microscopy .................................................................... 46 
2.5.2 Light scattering spectroscopy .............................................................................. 47 
2.5.3 Optical Coherence Tomography ......................................................................... 47 
2.6 Biospectroscopy .................................................................................................... 48 
2.6.1 Raman Spectroscopy .......................................................................................... 49 
2.6.2 Infrared Spectroscopy ......................................................................................... 49 
CHAPTER 3 ............................................................................................................... 50 
INFRARED SPECTROSCOPY ............................................................................... 50 
3.1 Vibrational Modes .................................................................................................. 51 
3.2 Clinical Need for Infrared Spectroscopy ................................................................. 52 
3.3 A Historical Overview of infrared Spectroscopy ...................................................... 53 
3.4 Applications of Infrared Spectroscopy .................................................................... 54 
3.5 Infrared Spectroscopy Instrumentation and Set-up ................................................ 58 
3.6 High Resolution Infrared Spectroscopy .................................................................. 60 
3.7 Thesis Objectives .................................................................................................. 61 
CHAPTER 4 ............................................................................................................... 62 
MATERIALS AND METHODOLOGY ...................................................................... 62 
4.1 Ethical Approval ..................................................................................................... 62 
4.2 Tissue Collection ................................................................................................... 62 
4.3 Histopathology ....................................................................................................... 62 
4.3.1 Tissue Samples .................................................................................................. 63 
4.3.2 Image creation .................................................................................................... 67 
4.4 Infrared Measurements .......................................................................................... 68 
4.4.1 High magnification infrared spectra ..................................................................... 70 
4.5 Data Analysis ......................................................................................................... 71 
4.5.1 Spectral Pre-Processing ..................................................................................... 72 
4.5.2 Chemometric Analysis ........................................................................................ 74 
4.5.3 Peak Assignments .............................................................................................. 75 
CHAPTER 5 ............................................................................................................... 76 
RESULTS ............................................................................................................... 76 
5.1 Review of Spectral Quality ..................................................................................... 77 
5.2 Univariate Analysis ................................................................................................ 89 
5.2.1 Derivative Spectra (Second Order) ..................................................................... 91 
5.2.2 Difference Spectra .............................................................................................. 99 
Page | 7 
 
5.3 Bivariate Analysis ................................................................................................ 103 
5.4 Multivariate Spectral Analysis .............................................................................. 105 
5.4.1 ‘Four Group’ Model ........................................................................................... 106 
5.4.2 ‘Two Group’ Model ............................................................................................ 116 
CHAPTER 6 ............................................................................................................. 124 
CONCLUSIONS .................................................................................................... 124 
7.1 Future Work ......................................................................................................... 129 
APPENDIX A ............................................................................................................ 132 
BIBLIOGRAPHY ....................................................................................................... 136 
 
 
Page | 8 
 
LIST OF ABBREVIATIONS 
 
AFI 
ANN 
ANOVA 
APC 
ATR 
BCSP 
 
C 
Ca 
CRC 
CaF2 
DNA 
EB 
EM 
EMR 
EMSC 
 
ETMI 
FICE 
 
FOB 
FPA 
FTIR 
GI 
H 
H&E 
HGD 
IEN 
IMA 
IR 
LDA 
 
Autofluorescence imaging 
Artificial neuronal network 
Analysis of variance 
Antigen-presenting cell 
Attenuated total reflectance 
Bowel cancer screening 
programme 
Carbon 
Calcium 
Colorectal cancer 
Calcium fluoride 
Deoxyribonucleic acid 
Expert Board 
Epithelial misplacement 
Endoscopic mucosal resection 
Extended multiplicative signal 
correction 
Endoscopic trimodal imaging 
Flexible image colour 
enhancement 
Faecal occult blood 
Focal Plane Array 
Fourier transform IR 
Gastrointestinal 
Hydrogen 
Haematoxylin & eosin 
High grade dysplasia 
Intra epithelial neoplasia 
Inferior mesenteric artery 
Infrared  
Linear discriminant analysis 
 
LGD 
LIFS 
 
LOSOCV 
 
MDT 
MINERVA 
 
 
MSI 
N 
NA 
NBI 
NHS 
NICE 
 
O 
OCT 
PC 
PCA 
PE 
PO2- 
RNA 
SD 
SMA 
STK1 
TEMS 
 
TNM 
UK 
3D 
 
Low grade dysplasia 
Laser-induced fluorescence 
spectroscopy 
Leave one sample out cross 
validation 
Multi-disciplinary team 
MId- to NEaR infrared 
spectroscopy for improVed 
medical diAgnostics 
Micro satellite instability 
Nitrogen 
Nucleic acid 
Narrow band imaging 
National health service 
National Institute for Clinical 
Excellence 
Oxygen 
O computer tomography 
Principal component 
Principal component analysis 
Perkin Elmer 
Phosphate 
Ribonucleic acid 
Standard deviation 
Superior mesenteric artery 
Serological thymidine kinase 
Transanal endoscopic 
mucosal resection 
Tumour node metastasis 
United kingdom 
3-dimensional 
 
 
Page | 9 
 
LIST OF FIGURES 
 
CHAPTER 1 
Figure 1.1: Anatomy of the large bowel(Genericlook.com 2010)        16 
Figure 1.2: Histological cross section of large bowel wall(CNX 2014)       17 
Figure 1.3: Haematoxylin and Eosin stained histological cross section of large bowel 
mucosa and submucosa(Parsa 2008)            18 
 Figure 1.4: The average number of cancer cases per year(Cancer Research UK 2010)
                   20 
Figure 1.5: Bowel cancer screening home kit(Public Health England 2013)      21 
Figure 1.6: A schematic representation of colorectal cancer growth and spread(Fraser 
2009)                    24 
Figure 1.7: A colonoscopic view of an advanced colon cancer with a large ulcerated 
and bleeding polypoid tumour projecting into the lumen of the bowel(Roy et al. 2012)
                   25 
Figure 1.8: A colonoscopic view of an early polyp cancer amenable to 
polypectomy.(Sherman 2009) The Outward appearance is very similar to that of an 
adenoma at the time of colonoscopy             26 
Figure 1.9: The histological classification for bowel cancer         28 
Figure 1.10: A modified adenoma-carcinoma progression model with acquired genetic 
abnormality at each stage of advancement(Fearon and Vogelstein 1990)       29 
Figure 1.11: Haggitt classification of invasive cancer in a sessile and pedunculated 
polyp(Bujanda 2010)                         33 
CHAPTER 2 
Figure 2.1: Description of a light as a wave                        39 
Figure 2.2: A schematic representation of the whole electromagnetic spectrum      40 
Carmine dye enhanced, and (Right:) narrow band imaging (Tanaka and Sano 2011)
                    45 
Figure 2.4: An example of Optical Coherence Tomography used to examine the 
retina of the eye in detail(Eye Site Texas 2015)          48 
 
 
Page | 10 
 
CHAPTER 3 
Figure 3.1: Variations of molecular bond movements         51 
Figure 3.2: An example of infrared absorption peaks and the molecular bond attributed 
to water and carbon dioxide             52 
Figure 3.3: Schematic simplified representation of the basic components of an infrared 
spectrometer                59 
 
CHAPTER 4 
Figure 4.1: Schematic representation of sections through the tissue block       65 
Figure 4.2: Calcium fluoride slide absorbance signal(Davis 2007)         66 
Figure 4.3:  Figure 4.3: Histological H&E slide of normal glands (left), marked by 
pathologist with a circle, with corresponding white light image (right)        67 
Figure 4.4: Schematic representation of Perkin-Elmer® detector raster movement.  
Each 4 coloured dots represent the acquisition of 16 pixels         69 
Figure 4.5: Schematic representation of Agilent® detector snake-like movement      70 
Figure 4.6: (Top left) Intensity map of the raw data with corresponding identification of 
region of interest for a glad with epithelial misplacement (Top Right).  Corresponding 
white light image for the sample below           73 
 
CHAPTER 5 
Figure 5.1: Mean spectra offset for all groups plotted with standard deviation. Green= 
Normal, Blue= Dysplasia, Red= Cancer, Orange= Polyp Cancer, Purple= Epithelial 
Misplacement               77 
Figure 5.2: Mean spectra with SD for all cases plotted together for Normal group       78 
Figure 5.3: Mean spectra with SD for all cases plotted together for Dysplasia group   79 
Figure 5.4: Mean spectra with SD for all cases plotted together for Cancer group      80 
Figure 5.5: Mean spectra with SD for all cases plotted together for Polyp Cancer group 
     81 
Figure 5.6: Mean spectra with SD for all cases plotted together for Epithelial 
Misplacement group              82 
Figure 5.7: Mean spectra for all cases plotted together for Dysplasia group post 
automated exclusion              85 
Page | 11 
 
Figure 5.8: Mean spectra for all cases plotted together for Cancer group post 
automated exclusion              86 
Figure 5.9: Mean spectra for all cases plotted together for Polyp Cancer group post 
automated exclusion              87 
Figure 5.10: Mean spectra for all cases plotted together for Epithelial Misplacement 
group post automated exclusion            88 
Figure 5.11: Mean spectra offset for all groups plotted with standard deviation and peak 
assignments labelled.  Green= Normal, Blue= Dysplasia, Red= Cancer, Orange= Polyp 
Cancer, Purple= Epithelial Misplacement           89 
Figure 5.12: Normal group derivatives; (Top) Mean spectra, (Middle) 1st order 
derivative, and (Bottom) 2nd order derivative for Normal group        93 
Figure 5.13: Dysplasia group derivatives; (Top) Mean spectra, (Middle) 1st order 
derivative, and (Bottom) 2nd order derivative for Dysplasia group        94 
Figure 5.14: Cancer group derivatives; (Top) Mean spectra, (Middle) 1st order 
derivative, and (Bottom) 2nd order derivative for Cancer group        95 
Figure 5.15: Epithelial Misplacement (EM) group derivatives; (Top) Mean spectra, 
(Middle) 1st order derivative, and (Bottom) 2nd order derivative for EM group      96 
Figure 5.16: Polyp Cancer group derivatives; (Top) Mean spectra, (Middle) 1st order 
derivative, and (Bottom) 2nd order derivative for Polyp Cancer group       97 
Figure 5.17: Cancer vs. Normal difference spectra        100 
Figure 5.18: Cancer vs. Dysplasia difference spectra                  101 
Figure 5.19: Cancer vs. Epithelial Misplacement difference spectra     102 
Figure 5.20: Cancer vs. Polyp Cancer difference spectra        103 
Figure 5.21: Graph demonstrating mean spectral differences in Four Group Model.  
Green = Normal group, Blue = Dysplasia group, Purple = Epithelial Misplacement 
group and Black = Abnormal combined cancer group with standard deviation plotted as 
shaded areas             107 
Figure 5.22: Histogram to show plot of Fratio vs. 25 Principal Components score    109  
Figure 5.23: PCA Scatter Plot (PC2 vs. PC3 vs. PC4) demonstrating maximal variance 
in Four Group Model.  Green = Normal group, Blue = Dysplasia group, Purple = 
Epithelial Misplacement group and Black = Abnormal combined cancer group      110 
Figure 5.24: PC loadings for PC 2, 3 and 4 with peak label assignments     111 
Figure 5.25: LDA Scatter Plot (LD1 vs. LD3) represents the clustering of pathological 
groups for the Four Group Model; each point represents a single spectrum.  Green= 
Page | 12 
 
Normal group, Blue+ Dysplasia group, Black= Abnormal group and Purple= Epithelial 
Misplacement group with standard deviation plotted as shaded areas     113  
Figure 5.26: Graph demonstrating mean spectral differences in Two Group Model.  
Purple= Epithelial Misplacement group and Black= Abnormal group     117 
Figure 5.27: Histogram to show plot of Fratio vs. 25 Principal Component scores    118 
Figure 5.28: PCA Scatter Plot (PC2 vs. PC3 vs. PC4) demonstrating maximal variance 
in Two Group Model.  Purple= Epithelial Misplacement group and Black= Abnormal 
combined cancer group           119 
Figure 5.29: PC loadings for PC 2, 3 and 4 with peak assignment labels        120 
Figure 5.30: LDA Histogram (LD1 vs. LD2) representing the clustering of the two 
groups in the Two Group Model; Purple= Epithelial Misplacement group and Black= 
Abnormal group            121 
 
CHAPTER 6 
Figure 6.1: (Above) The white light image for a cancer sample and (Below left): The 
corresponding intensity image with limited glandular landmark for epithelial selection, 
as seen on the right               127 
Page | 13 
 
LIST OF TABLES 
CHAPTER 1 
Table 1.1: Tumour Node Metastasis (TNM) classification         23 
Table 1.2: Various presenting shapes of adenoma(Clouston and Walker 2013)      31 
 
CHAPTER 4 
Table 4.1: Initial total number of patient and study samples for each of the five 
pathological groups              66 
 
CHAPTER 5 
Table 5.1: Actual sample numbers per group          76 
Table 5.2: Total number of spectra per group           84 
Table 5.3: Peak assignments from the literature          90 
Table 5.4: Sum of peak area ratios for Group comparisons. *NA= nucleic acids    104 
Table 5.5: Leave one sample out cross validation confusion matrix table with average 
sensitivity and specificity.  EM= Epithelial Misplacement       112 
Table 5.6: Leave one sample cross validation sensitivity and specificity results for the 
revised Four Group Model using only 178000 spectra per group. EM= Epithelial 
Misplacement             114 
Table 5.7: A confusion matrix table based on classification of cases per group by 
majority percentage classified spectra, with average sensitivity and specificity.  
Correctly classified cases in bold.  EM= Epithelial misplacement      115 
Table 5.8: Leave one sample out cross validation confusion matrix. EM= Epithelial 
Misplacement             122 
Table 5.9: A confusion matrix table based on classification of cases per group by 
majority percentage classified spectra.  Correctly classified cases in bold. EM= 
Epithelial misplacement           122 
  
Page | 14 
 
LIST OF APPENDIX A FIGURES 
Figure 1.1: Mean spectra for all cases plotted together for Dysplasia group post manual 
exclusion             132 
Figure 1.2: Mean spectra for all cases plotted together for Cancer group post manual 
exclusion             133 
Figure 1.3: Mean spectra for all cases plotted together for Polyp Cancer group post 
manual exclusion            134 
Figure 1.4: Mean spectra for EM group post manual exclusion       135  
Page | 15 
 
CHAPTER 1 
THE COLORECTUM AND COLORECTAL CANCER 
 
 
This thesis presents the use of high resolution infrared spectroscopy as a 
potential diagnostic tool for the detection of cancer in the colon and in particular 
the differentiation of cancer from other benign pathological phenomena.  
Chapter 1 introduces the colon and rectum and provides a general background 
of current UK colorectal cancer management, highlighting the incidence and 
rationale for population screening along with stage and classification of 
colorectal cancer. The management of various colorectal polyps is discussed, 
and a conclusion is reached with a general introduction to the benign 
pathological phenomenon of epithelial misplacement, which this thesis focuses 
on again in later chapters. 
 
1.1 The Colon and Rectum 
The large intestine, or colon, is a long muscular tube, the primary function of 
which is for passage of waste material through to the rectum where it is stored a 
variable amount of time before expulsion, and secondarily for water re 
absorption along its length. Fairly liquid-type stool passes from the small 
intestine where the majority of nutrient absorption occurs, into the large intestine 
and water is reabsorbed along its length to form hard, formed stool at the 
rectum. 
 
1.1.1 Anatomy 
The large intestine compromises the appendix, caecum, colon and rectum and 
is approximately 150cm long with a diameter of between 3.5cm and 5cm in the 
adult (see Figure 1.1).  
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Figure 1.1: Anatomy of the large bowel(Genericlook.com 2010) 
 
Along the length of the colon are markings called haustra which give the colon 
its distinctive concertina or saccular appearance. They are formed because of 
bands running the length of the colon called taeniae coli which are shorter than 
the length of the colon and cause the colon to be sacculated between, forming 
the haustra. Haustral contractions are partly responsible for the movement of 
waste along the colon and occur approximately every 25 minutes and push the 
waste from one haustra to the next en mass. In combination with peristaltic 
movement of the muscle bowel wall, food is moved from the caecum to the 
rectum in approximately 6 hours, depending on the individual (can take days in 
others).   
 
1.1.2 Blood supply 
The blood supply to the colon is from two main branches off the abdominal 
aorta, the superior mesenteric artery (SMA) and inferior mesenteric artery 
(IMA). The SMA gives the middle, right and ileo-colic arteries- supplying 
caecum to 2/3 of the way along the transverse colon. A marginal artery variably 
connects SMA branches to branches from the IMA system which then supplies 
the descending colon, sigmoid colon and recto-sigmoid junction. Lymphatic 
drainage to local nodes follows the blood supply.  
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1.1.3 Histology 
The large intestine has a similar general histological structure along its length. It 
is composed throughout of relatively flat mucosa with only a small variation in 
the amount of lymphoid tissue, lymphoglandular complexes and epithelial 
constituents.(Shepherd 2002) The normal layers of the bowel wall can be seen 
in Figure 1.2.  
 
 
Figure 1.2: Histological cross section of large bowel wall(CNX 2014) 
 
Most of these layers can be seen in the biopsy specimen in Figure 1.3 which 
had been stained with Haematoxylin and Eosin to give the structures a 
particular colour. Haematoxylin is a natural dye which stains the nucleus of the 
cell and cytoplasm rich in ribonucleoprotein a blue/black colour. Eosin is an 
aniline acid dye that stains cytoplasm, connective tissue and muscle 
pink/orange. Thus cell structures and tissue can be differentiated according to 
particular depth of stain and pattern. 
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Figure 1.3: Haematoxylin and Eosin stained histological cross section of 
large bowel mucosa and submucosa(Parsa 2008) 
 
The epithelium is the outermost layer of mucosa and forms the inner bowel wall. 
It is composed of cell crypts arranged in parallel and lined by cells that secrete 
mucin, which aids movement of the stool along the length of the gut, and 
absorptive cells. It is from this layer that adenocarcinomas arise.  
The proliferation zone is found at the base of the crypts where most new cell 
formation occurs and a high volume of dividing cells can be seen here. The 
crypts are embedded in lamina propria, the connective tissue of the mucosa. 
The mucosa sits on a submucosal layer of connective tissue which contains 
vascular, lymphatic and parasympathetic cells (Meissner’s submucosal plexus). 
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A thin muscle layer, the muscularis mucosae, separates the mucosa from the 
submucosa. Outside the submucosa is the muscularis propria, a thick muscle 
layer consisting of inner circular and outer longitudinal smooth muscle layers 
separated by a layer of connective tissue containing Auerbach’s myenteric 
plexus.  
The subserosa, another connective tissue layer, and the serosa surround the 
large intestine, the outermost layer of which, in some areas, is in continuity with 
the layers of the abdominal wall known as the peritoneum. 
 
1.2 Colorectal cancer in the UK 
Bowel cancer is the fourth most common cancer in the UK (2010), accounting 
for 13% of all new cases. It is the third most common cancer in both males 
(14% of the male total) and females (11%).(Cancer Research UK 2010) 
In 2011, there were 41,581 new cases of bowel cancer in the UK: 56% in men 
and 44% in women, giving a male: female ratio of 1.3:1. The crude incidence 
rate shows that there are around 75 new bowel cancer cases for every 100,000 
males in the UK and around 56 for every 100,000 females.(Public Health 
England 2013) Approximately 55% of adult bowel cancer patients (54% of men 
and 56% of women) in England survived their cancer for five years or more in 
2005-2009.  
Bowel cancer incidence is strongly related to age, with the highest incidence 
rates being in older men and women. In the UK between 2009 and 2011, an 
average 43% of bowel cancer cases were diagnosed in people aged 75 years 
and over, and 95% were diagnosed in those aged 50 and over, see Figure 1.4. 
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Figure 1.4: The average number of cancer cases per year in the UK(Cancer 
Research UK 2010) 
 
1.3 National Bowel Cancer Screening 
There is a time delay in the development of bowel cancer which gives a window 
of opportunity for effective population screening. Early diagnosis and removal of 
polyps reduces the incidence of colorectal cancer and earlier detection of 
colorectal cancer helps to identify these lesions at an earlier stage.(Loughrey 
and Shepherd 2015) Regular bowel cancer screening has been shown to 
reduce the risk of dying from bowel cancer by 16%.(Hewitson et al. 2008) One 
study investigating the use of a one-off flexible sigmoidoscopy found a 31% 
reduction in mortality in the screened group compared to the control 
group.(Atkin et al. 2010) 
The diagnosis of bowel abnormalities is either via history, examination and 
special investigation requested by a clinician or can be via the NHS Bowel 
Cancer Screening Programme (BCSP). Screening is offered to the whole UK 
population every two years to all men and women aged 60 to 69 (although by 
September 2012, 40 of the 58 local screening centres had also started inviting 
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to an extended population of up to 75 years old). A pilot scheme offering flexible 
sigmoidoscopy in six bowel cancer screening centres has been introduced, 
offered on a one-off basis between the ages of 55 and 64, to be rolled out 
nationally by 2016.(Public Health England 2013) 
 
1.3.1 The National Bowel Cancer Screening Programme 
Men and women eligible for screenings receive an invitation letter explaining the 
programme, and information leaflet, “Bowel Cancer Screening - The Facts”. 
 
 
Figure 1.5: Bowel cancer screening home kit(Public Health England 2013) 
 
About a week later, a faecal occult blood (FOB) test kit is sent out along with 
step-by-step instructions for completing the test at home and sending the 
samples to the hub laboratory (Figure 1.5). This test is specifically designed to 
detect a tiny volume of blood in the faeces at an early stage before the person 
can see it themselves. 
The test is then processed and the results sent within two weeks. 94% of the 
tested population will receive a normal result and will be returned to routine 
screening and invited for bowel cancer screening every two years hence (if still 
within the eligible age range for routine screening) and 2% will receive an 
abnormal result. They will be referred for further investigation and usually 
offered a colonoscopy. 4% receive an unclear result and the FOB test is 
repeated. Most people who repeat the test will then go on to receive a normal 
result.(Public Health England 2013) 
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A colonoscopy is an investigation routinely performed in the outpatient setting. It 
requires the patient to take a laxative at home for the preceding two days, 
coupled with a low-residue diet to clear out the bowel and thus give the 
endoscopist the best possible view of the bowel wall on the day of the 
procedure, enabling them to identify any abnormal pathology more easily. The 
patient is admitted to hospital usually only for one day, and the colonoscopy is 
performed with the patient awake but often sedated. It enables the clinical 
endoscopist to look directly at the lining of the large bowel. It is an excellent tool 
to detect overt pathology in the large bowel including inflammation, polyps and 
suspected cancer. A colonoscope is passed into the back passage and guided 
around the bowel using a wheel controller connecting the scope to a monitor. 
The benefit of endoscopy over radiological investigation is that it gives the 
clinician opportunity to biopsy any abnormality found, and remove polyps via the 
instrument channel of the endoscope (polypectomy), and if the surgeon 
performs the endoscopy, for future operation planning if necessary.  
Polyps may be excised whole with a wire snare combined with diathermy. All 
tissue is sent to the histopathology lab for further analysis. Of those patients 
who undergo a screening colonoscopic investigation; 
 Five in 10 people will have a normal result. 
 Four in 10 will be found to have a polyp 
 One in 10 people will be found to have cancer 
All tissue taken at the time of colonoscopy is placed in formaldehyde and then 
sent to the histopathology laboratory where it is embedded in paraffin. Thin 
tissue sections, three to four micrometers in thickness, are prepared from the 
processed paraffin blocks on to a glass slide and sent for routine staining which 
change colour in the presence or absence of varying pathologies (haematoxylin 
and eosin, H&E). A consultant Histopathologist then reviews the slides and 
reports any abnormal pathology at a cellular level.  For those patients who are 
discovered to have a polyp on their colonoscopy there is a specific NICE 
guideline for managing follow-up (NICE Clinical Guideline 118, 2011).(National 
Institute for Health and Care Excellence 2011). Patients are stratified according 
to risk (size number and type of polyp) and plan made for repeat colonoscopic 
follow-up surveillance at a time depending on the risk assessment.  
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1.4 Management of Colorectal Cancer 
Guidelines exist from the National Institute for Health and Care Excellence 
(NICE) to standardise the care received by patients with bowel cancer 
throughout the NHS in the UK. Management of colorectal cancer in secondary 
care begins with appropriate diagnosis of the disease and this is based on a 
number of special investigations which are offered to the patient (usually 
including tissue diagnosis and CT scan to check for disease spread). The stage 
of the cancer can then be assessed according to the Tumour Node Metastasis 
(TNM) scoring system(Loughrey et al. 2014) (See Table 1.1). It should be 
emphasised that, in the UK, pathologists use the TNM 5 modification of the 
TNM system as subsequent versions are not based on sound literature 
evidence and have not found favour in the UK and Western Europe. The TNM 5 
version is reproduced below. 
 
TUMOUR NODE METASTASIS 
T1 tumour confined to 
submucosa 
N0 no lymph nodes 
contain tumour cells 
M0 no metastases to 
distant organs 
T2 tumour into (but not 
through) the  muscularis 
propria 
N1 tumour cells present 
in up to 3 regional 
lymph nodes 
M1 metastases to distant 
organs 
T3 tumour into (but not 
through) the subserosa 
N2 tumour cells present 
in 4 or more regional 
lymph nodes 
  
T4 Tumour penetrated 
through the serosa and 
peritoneal surface.  
T4a = extends directly 
into other nearby 
organs/structures  
T4b = with peritoneal 
involvement only. 
    
Table 1.1: Tumour Node Metastasis (TNM) classification. 
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Stage of disease can then be ascertained using the TMN score and evidence of 
spread and graded according to histological type (low-high), see Figure 1.6. 
Morbidity and mortality outcome figures are predicted according to stage and 
grade of tumour at presentation.  
 
 
Figure 1.6: A schematic representation of colorectal cancer growth and 
spread(Fraser 2009) 
 
Practical management of patients varies according to their TMN stage (Clinical 
Guideline 131). Depending on whether the cancer can be removed by a surgical 
operation, the patient may be offered pre-operative chemotherapy to try and 
reduce the bulk of the tumour invasion and enable operative management.  The 
patient may then be offered adjuvant chemotherapy following their operation 
according to the stage of their disease with the aim of targeting any cancer cells 
in the blood or lymph circulation and reduce the risk of local or distant 
recurrence. This whole process has to be done in accordance with the NHS 
National Service Framework 62 day cancer treatment target (time from referral 
to treatment).(NHS England 2011) 
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1.4.1 Management of Early Polyp cancers 
Patients found to have a polyp cancer are by definition pT1 as the tumour is 
confined to the submucosa of the polyp (identification at an early stage means 
that the cancer has not spread far though the bowel wall, see Figure 1.7 and 
1.8, and Table 1.1). The mainstay of treatment for early cancers is local 
resection. This is usually in the form of endoscopic polypectomy at the time of 
colonoscopy. A more formal resection may be advocated on the basis of the 
local resection margin. If the cancer is very close or present at the polypectomy 
margin, the clinical decision may be for surgical intervention, i.e. colectomy, 
depending on the outcome of the local colorectal cancer multidisciplinary team 
meeting discussion after their assessment of the patient’s risks and benefits for 
surgery. Patients fit for surgery will have the advantage of detecting nodal 
metastasis and a final formal pathological nodal stage that will decide if 
adjuvant chemotherapy is required. 
 
 
Figure 1.7: A colonoscopic view of an advanced colon cancer with a large 
ulcerated and bleeding polypoid tumour projecting into the lumen of the 
bowel(Roy et al. 2012)  
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Figure 1.8: A colonoscopic view of an early polyp cancer amenable to 
polypectomy.(Sherman 2009) The endoscopic appearance is very similar 
to that of an adenoma at the time of colonoscopy 
 
1.5 Colorectal cancer 
The natural history of colorectal cancer is well documented, and a neoplastic 
(tumour- forming) precursor identified, the adenoma or adenomatous polyp. The 
adenoma-carcinoma sequence has been researched in great depth and it is 
generally accepted that the majority of colorectal cancers arise from such 
adenomas.(Lockhart-Mummery 1928; Muto et al. 1975; Winawer et al. 1997) 
A near obligate precursor to cancer, intra-epithelial neoplasia (IEN) occurs in 
the epithelial tissues of the mucosa, as low or high grade dysplasia, and shares 
phenotypic and genotypic similarities with invasive disease on the causal 
pathway leading from normal tissue to cancer. In addition, IEN serves as a 
significant risk marker for cancer. Subjects with IEN, particularly those with high 
grade IEN, are at significantly higher risk than unaffected individuals of 
developing invasive cancer in the same tissues.(Kelloff et al. 2004) Only a small 
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proportion of polyps (1-10%) develop into invasive bowel cancer.(Scholefield 
2000) Indicators for progression from adenomas to cancer include large size, 
villous histology and high grade dysplasia.(Terry et al. 2002) 
Dysplasia is defined as “an unequivocal neoplastic alteration of epithelium 
which has the potential to progress to invasive malignancy but remains confined 
within the basement membrane of the epithelium within which it arose”.(Riddell 
et al. 1983) Dysplasia is classified as either low grade (LGD) or high grade 
(HGD) based on its histological appearances. HGD has a higher malignant 
potential than LGD and malignant transformation classically occurs through a 
stepwise progression of the pathology. 
 
1.5.1 Pathogenesis of Colorectal Cancer  
The progression of normal cells to cancer cells is multi-factorial. There has been 
much debate as to the influence of diet and lifestyle choice, such as cigarette 
smoking and obesity to the risk of cancer.(Hsing et al. 1998; Terry et al. 2002) It 
is estimated that 35% of colorectal cancer (CRC) risk may be explained by 
heritable factors.(Lichtenstein et al. 2000) Inherited genetic factors have an 
influence in a subset of patients who develop CRC: certain families have 
hereditary gene mutations which predispose them to developing colorectal 
cancers (and often at a younger age) such as Lynch syndrome, Gardner’s 
syndrome, effectively a subtype of Lynch syndrome and many more (several of 
which are uncharacterised).(Sehgal et al. 2014; Zhang et al. 2014; Shiovitz et 
al. 2014) There is also an established association with some inflammatory 
bowel conditions and CRC, especially ulcerative colitis and Crohn’s 
disease.(Eaden et al. 2001; Mudter and Neurath 2007; Atreya and Neurath 
2008)  
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Figure 1.9: The histological classification for bowel cancer 
 
Generally CRC is thought to arise following the accumulation of genetic and 
acquired epigenetic changes that transform normal glandular epithelial cells into 
invasive adenocarcinomas (see Figure 1.9). These transformative steps are 
described in the classic tumour progression model.(Fearon and Vogelstein 
1990) Since this model was originally proposed, our understanding of the 
molecular pathogenesis has advanced considerably and led to numerous 
revisions of the Vogelstein & Fearon model,(Pritchard and Grady 2011) (see 
Figure 1.10), mostly through huge variety in genetic mutation and types of 
polyp.  Mutations in genes responsible for DNA repair, chemical processing and 
the inflammatory response are all thought to have a role. For example, serrated 
polyps are associated with microsatellite instability (MSI) and abnormality in 
DNA methylation whereas adenomas arise through inactivation of APC tumour 
suppressor genes and display chromosome instability.(Noffsinger 2009) 
Although several of the molecular changes have been defined, many of the 
steps in the progression to cancer are still unclear and the source of much 
ongoing research.  
 
Histological classification for bowel cancer 
Normal epithelium Hyperplastic 
Serrated 
Dysplasic 
(Adenoma) 
Low Grade 
Dysplasia (LGD) 
High Grade 
Dysplasia (HGD) 
Neoplastic 
(Adenocarcinoma) 
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Figure 1.10: A modified adenoma-carcinoma progression model with 
acquired genetic abnormality at each stage of advancement(Fearon and 
Vogelstein 1990) 
 
It is important to understand the molecular biology of cancer progression and its 
correspondence with histological change in the cells so that they can be 
targeted at an early stage, to try and modulate or prevent the transition of these 
cells from benign to cancerous.  
 
1.6 Colorectal polyps 
Defined as any lesion raised above an epithelial surface, there are many types 
of large intestinal polyp, which require careful assessment to ensure accurate 
diagnosis by the histopathologist. Polyps resected at endoscopy represent a 
significant workload for the histopathology team, and this has increased with the 
advent of the BCSP and its surveillance protocols. Significant diagnostic 
disagreement has been demonstrated between histopathologists for diagnosis 
of specific pathological entities(Wong et al. 2009) and has prompted the 
development of various research techniques to aid this process. Polyps can 
originate from both mucosal and submucosal tissues. They can be classified 
according to size, shape and histology. 
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1.6.1 Hyperplastic and other serrated polyps:  
Hyperplastic polyps account for the greatest number of large bowel polyps and 
are commonest in the sigmoid colon and rectum. They account for about 30% 
of all polyps detected in the bowel cancer screening programme in the UK. 
They appear endoscopically as pale nodules of the colorectal mucosa and are 
generally small, less than 0.5cm in diameter, and sessile. They show some 
biochemical similarities to large bowel carcinoma but the current belief is that 
they represent little or no neoplastic potential. (Shepherd 2002) They do not 
usually display the critical abnormalities in APC and p53 gene mutations that 
predispose to colorectal cancer. They show a characteristic serrated phenotype, 
a morphological change shared with other less common polyps found especially 
in the right colon. The latter appear to have more neoplastic potential than 
standard hyperplastic polyps of the left colon and rectum and may demand 
enhanced surveillance strategies. 
 
1.6.2 Adenomatous polyp:  
The adenoma itself is classified as a benign polyp of the large bowel. However 
because the adenoma-carcinoma is thought to be the most important pathway 
for development of (sporadic) colorectal malignancy, identification and removal 
of adenomas has become the high priority during colonoscopy(Public Health 
England 2013). Most carcinomas arise from a pre-existing adenoma although 
most adenomas will not become malignant.  Adenomas are dysplastic by 
definition and display disordered, neoplastic epithelial growth patterns with 
failure of maturation and differentiation. Morphological features change with 
grade of dysplasia (worsening; mild to moderate to severe, or low to high grade) 
with increasingly enlarged, spheroidal and hyperchromatic nuclei with 
disorientation of the nuclei to the basement membrane ‘polarity’.(Shepherd 
2002; Clouston and Walker 2013) 
 They are classified according to histological morphology: tubular (most 
common), villous and tubulovillous. The most important factors for predicting the 
development of malignancy are size, grade of dysplasia (low or high) and the 
villousness (the morphology of the polyp). Endoscopically adenomas are 
obvious above approximately 8mm in size because they have a rich vascularity 
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and appear red and lobulated, their exact shape dependent on the villousness 
and whether they are sessile or pedunculated (see Table 1.2). Adenomas can 
also be flat. These tend to be found in younger patients and exhibit higher 
grades of dysplasia and are more likely to harbour foci of invasive 
malignancy.(Clouston and Walker 2013) They are also less likely to be 
identified via the BCSP because they bleed less readily and are therefore not 
picked up on FOB testing. There are also various genetic disorders where 
patients display great number of polyps at a young age and are therefore at 
much higher risk of developing a colorectal cancer. 
 
 
 
Pedunculated adenoma 
 
 
 
Semi-pedunculated adenoma 
 
 
Sessile adenoma with 
lobulated appearance 
 
 
Flat adenoma 
Table 1.2: Various presenting shapes of adenoma(Clouston and Walker 
2013)  
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1.6.3 Mixed polyps:  
These are polyps which demonstrate features of both adenomatous polyps and 
serrated polyps. They make up less than  1% of all adenomatous polyps and 
represent a polymorphous population of polyps, including collision lesions, 
where two forms of polyp have collided and joined.(Clouston and Walker 2013) 
 
1.6.4 Carcinomatous Polyps:  
Defined as a polyp in which cancer has invaded by direct continuity through the 
muscularis mucosae into the submucosa (usually on a background of low/high 
grade dysplasia), this can either be as a focus of invasive cells often in the 
centre of the polyp invading into the stalk, or the entire polyp may be composed 
of adenocarcinomatous tissue (having once had an adenomatous component 
but since destroyed by the cancer). They demonstrate architectural and 
cytological abnormalities within their epithelium and clear evidence of invasion 
with an appropriate stromal reaction (in the form of tumour-associated fibrosis 
or desmoplasia). As previously stated, the prevalence of adenocarcinoma in an 
adenomatous polyp is dependent on size, grade of dysplasia and villosity of the 
pre-existing adenoma. Thus, large carpeting villous adenomas have the highest 
likelihood of harbouring foci of invasive malignancy. In one study, 6.4% of right 
colonic adenomas showed malignant change, 8.0% of left sided colonic 
adenomas showed malignancy, whereas 23% of rectal adenomas showed 
malignancy.(Nusko et al. 1997) 
Less than 5% of all adenomas actually demonstrate evidence of invasive 
malignancy and they are usually well delineated, without evidence of vascular 
spread and can often be effectively treated by local excision (this is 
polypectomy at time of colonoscopy or Trans Anal Endoscopic Mucosal 
Resection (TEMS procedure) (if low rectal). The endoscopist may also choose 
to tattoo the site of the polyp at the time so that the area is easier to find 
subsequently if necessary. Indeed, in BCSP, all endoscopists are mandated to 
tattoo the site of a polyp over 10mm in diameter because of the potential risk 
that that polyp may be cancerous and thus require subsequent surgery.  
Macroscopically carcinomatous polyps are more likely to be irregular with 
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bleeding from surface ulceration and firmer to palpation, and this becomes more 
obvious as the cancer progresses to be larger and more advanced, but these 
overt signs are often absent and it can be very difficult to tell an adenoma from 
and early polyp cancer at the time of colonoscopy.  
The initial management for most polyp cancers and adenomas, therefore, is 
endoscopic resection and histopathological analysis of the specimen removed. 
Further surgical management with radical resection is fairly contentious; the 
evaluation of the margin of excision in polypectomy specimens is done by 
measuring the distance from the deepest invading tumour cells to the 
cauterized/excised margin off the glass slide. In well orientated intact 
polypectomy specimens with polyp cancer, the pathologist will also provide the 
level of invasion using Haggitt classification for pedunculated polyps or 
Kikuchi/Kudo for sessile polyps including measurements of the depth and width 
of the invasive component. Margin involvement, vascular invasion, poor 
differentiation and depth/level of invasion may indicate the need for surgical 
resection,(Riddell et al. 1983) which aims to prevent local recurrence and 
harvest lymph nodes for evidence of involvement (and therefore possibility of 
distant metastases) and assess the TNM status.(Haggitt et al. 1985) 
 
 
Figure 1.11: Haggitt classification of invasive cancer in a sessile and 
pedunculated polyp(Bujanda 2010) 
 
Page | 34 
 
Depending on the overall pathological assessment, the status of the excision 
margin and the level of invasion of the polyp cancer, the Multi-Disciplinary Team 
will make a decision whether resection of the area of the polyp is required. This 
may involve a major operation with a significant risk of morbidity and mortality to 
the patient. It is extremely important, therefore, that a correct and early 
diagnosis is made within an appropriate time-frame for challenging diagnostic 
cases, with an ultimate aim to prevent the spread of cancer, and direct 
subsequent management of the patient.  
 
1.7 Epithelial Misplacement 
Epithelial misplacement (EM) is a histological phenomenon which quite literally 
describes the misplacement of epithelium from the mucosa into the submucosal 
region away from its place of origin. It was first described in detail as part of a 
characterisation of the genetic syndrome called Peutz-Jeghers syndrome, 
whereby mucocutaneous pigmentation is associated with “hamartomatous” 
polyps. A rare autosomal dominant condition, this disease affects approximately 
1 in 100,000 in the West. Patients display a mutation of the serological 
thymidine kinase (STK1) gene, resulting in polyps throughout the gut, 
nasopharynx and urinary system, but most commonly in the small intestine. 
Large polyps subject to high forces from gut motility were postulated to be likely 
to be subject to varying degrees of trauma, causing bleeding and translocation 
of the epithelium. The resulting EM in these cases was often dramatic and 
involved all layers of the bowel wall, including in the subserosa, where mucus 
cysts were seen.(Shepherd et al. 1987) The histological features observed 
demonstrated considerable mimicry of adenocarcinoma, so much that the early 
literature rates of small intestinal carcinoma in Peutz-Jeghers syndrome may 
have been falsely uplifted due to the misdiagnosis of EM.(Bartholomew et al. 
1957; Shepherd et al. 1987) Misplacement of dysplastic epithelium in Peutz-
Jeghers polyps has more recently been described as well, further complicating 
the diagnosis.(Petersen et al. 2000) 
Evidence of EM has also been found in inflammatory polyps at the anorectal 
junction, associated with diverticulosis, and at the site of stomas and in 
association with mucosal prolapse, all involving large polyps under high tensile 
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strain. EM has also been identified in cases of serrated polyps, small 
hyperplastic polyps of the left colon and rectum, and in sessile polyps of the 
right colon, known as inverted hyperplastic polyps, perhaps now better 
classified as sessile serrated lesions with epithelial misplacement.(Sobin 1985; 
Shepherd et al. 1987; Yantiss et al. 2001) 
 
1.7.1 Epithelial Misplacement in colonic polyps: 
EM was first described by Muto and colleagues in adenomatous polyps of the 
colon.(Muto et al. 1973) It was noted that EM was particularly prevalent in 
polyps of the sigmoid colon, and they were the first to characterise the 
associated morphological features. Colonic adenomas often show features of 
misplaced epithelium in the submucosal stalk (“pseudoinvasion”), particularly in 
those that are large and located in the sigmoid colon.(Yantiss et al. 2002) 
Stalked polyps were also thought to be subject to high propulsive force in the 
colon, in particular in those patients with another common benign condition of 
diverticular disease (a totally unrelated pathology of the (usually) sigmoid colon 
associated with diverticula; outpouchings of the gut wall, with thickening of the 
muscularis propria muscle layer) which causes the internal propulsive forces to 
be even higher. These forces within the colon, to a greater or lesser degree, 
cause trauma to stalked polyps by torsion. The proposed mechanism of the 
pathology is initially driven by ischaemia through a twisting movement of the 
polyp which cuts off its blood supply and then the surface consequently 
ulcerates and epithelium is traumatically moved from the surface of the polyp 
into the central volume. It is the process of recurrent episodic ischaemia and 
surface damage that is thought to frequently lead to the phenomenon of 
EM.(Muto et al. 1973)  
EM is characterised by the misplacement of surface epithelium into the central 
core of the polyp i.e. epithelium is seen in normal submucosa where it is not 
characteristically found. It is this feature that mimics invasive adenocarcinoma, 
in which the neoplastic epithelium migrates from its surface position because it 
is invading the submucosa. The epithelium in the submucosa of the adenoma 
typically appears cytologically similar to that of its surface and is usually 
accompanied by lamina propria tissue. Haemosiderin deposits are often 
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observed, in keeping with a traumatic cause for its presence, with epithelial 
necrosis and haemorrhage leading to that pigment accumulation. Mucus lakes 
are also classically described as the epithelium continues to produce mucus 
from goblet cells now buried under the surface and this has no way of being 
expelled and so it collects in large characteristic pools. 
EM in adenomas may resemble adenocarcinoma infiltrating the stalk of the 
polyp, and it can be very difficult to tell the difference between the two when 
assessed by a histopathologist, and impossible for the endoscopist at time of 
colonoscopy.  Histologically the two often have very similar features (including 
glandular epithelial abnormalities, the shape of glandular nests, and the 
presence of cystic gland and lamina propria, and haemosiderin deposits) which 
can complicate the diagnosis.(Shepherd and Griggs 2015) There may be 
evidence of acute necrosis of the surface of the adenomatous polyp, 
underpinning the traumatic mechanism of EM. Isolated glands without the 
accompanying lamina propria, tumour budding, evidence of vascular invasion 
and poor cell differentiation are all features that favour the presence of invasive 
adenocarcinoma. 
 
1.8 Clinical Diagnostic Need 
Increasing numbers of cases of EM have been seen in recent years which are 
attributed to the advent of the BCSP in recent years.  It is thought that because 
sigmoid polyps are predisposed to bleeding, more patients are preferentially 
picked up via the faecal occult blood testing (at home testing) and therefore 
more polyps are being found at colonoscopy and removed and sent for 
histological analysis. It is likely that these polyps will continue to be seen with 
increasing frequency (Clouston and Walker 2013) and cause more of a problem 
for the diagnosis of polyp cancers for clinicians. There are no endoscopic, 
histopathological or clinical methods to reliably differentiate cancer from EM, but 
clearly it is extremely important to correctly identify the cancer cases from those 
of EM because of the clinical implications, difference in patient management 
(polypectomy versus colectomy)(Hurley et al. 2013), and patient reassurance.  
Pathologists only have routine histopathological processing of tissue (with 
stains) to make the diagnosis.  This traditionally uses special stains to identify 
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cells or areas of interest in the tissue based on contrasting colours within a 
sample and are, in the most part, reliable. Immunohistochemistry for commonly 
used markers including E-Cadherin, Collagen IV, MMP-1 and p53 have been 
promoted(Mueller et al. 1997; Hansen et al. 1999; Yantiss et al. 2001; Yantiss 
et al. 2002) to aid diagnosis. The morphology of the tissue cells and tissue 
architecture can be visualised and from this a diagnosis is made, although 
these do not always confer benefit for the difficult intermediate lesions. 
Analysis of tissue using traditional staining techniques is technically challenging, 
time-consuming and user-dependent, as with most acquired skills it is generally 
reliable in cases with some obvious pathology, however can be very limited in 
difficult cases where the pathology of one disease state approaches the 
other.(Clouston and Walker 2013)   
Recently described as the “diagnostic conundrum of the century”,(Shepherd 
and Griggs 2015) it is sometimes so difficult to differentiate between EM and a 
focus of carcinoma in an adenomatous polyp that the local hospital GI 
Histopathologist is unable to settle on a diagnosis.  Diagnostic agreement at 
both regional and national level between expert pathologists has not always 
been unanimous(Turner et al. 2013) and in 2009 the BCSP established a 
National Expert Board (EB) to assess the problem and to address difficult 
diagnostic cases. Funded by the BCSP in England, over 200 individual cases 
have so far been through the EB. The board compromises three GI Registry 
Consultant Histopathologists who each review all the cases blinded. The 
original slides are sent to each Consultant in turn and they each provide a 
diagnosis and send on to the next. An overall diagnosis is made by majority 
consensus and a letter written back to the original pathologist. Even so, there 
are cases where the EB has been unable to make a definitive diagnosis 
because one or more expert pathologist has provided an ‘equivocal’ diagnosis. 
Although absolutely vital, this process is obviously time-consuming, expensive 
and as a consequence may delay diagnosis for the patient and onward 
management decisions.   
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CHAPTER 2 
VIBRATIONAL SPECTROSCOPY 
2.1 Biophotonics 
Biophotonics is the combination of biology and photonics; concerning 
generation, emission, transmission, modulation, detection, amplification, and 
sensing of light.(Bellisola and Sorio 2012) Biophotonic technologies can 
objectively measures the changes associated with cancer progression, such as 
change in genes, proteins, metabolites, morphologic, and other detectable 
traits.  
Spectroscopy is specifically the measurement of the interaction between 
radiated energy and matter. Vibrational spectroscopy, incorporating both 
infrared (IR) and Raman spectroscopy, is the analysis of the spectra produced 
by the interaction of light with the vibration states of molecular bonds. They 
provide information about the structure of a molecule. 
 
2.2 What is light? 
Faraday proposed in 1847 that light was a high-frequency electromagnetic 
vibration, which could propagate even in the absence of a medium such as the 
ether. James Clark Maxwell found that self-propagating electromagnetic waves 
would travel through space at a constant speed, which happened to be equal to 
the previously measured speed of light, and in 1862 proposed that light was a 
form of electromagnetic radiation (EMR) in wave formation (See Figure 2.1).  
 
Page | 39 
 
 
Figure 2.1: Description of a light as a wave 
 
The frequency of the wave determines its colour: 4×1014 Hz is red light, 
8×1014 Hz is violet light (wavelengths in the range of 700 nm (700×10−9 m) to 
400 nm respectively), and in between these are all the other colours of the 
rainbow in visible light– between the infrared, with longer wavelengths and the 
ultraviolet, with shorter wavelengths. Generally, EMR is classified by 
wavelength into radio, microwave, infrared, the ‘visible light’ region, ultraviolet, 
X-rays and gamma rays, see Figure 2.2. 
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Figure 2.2: A schematic representation of the whole electromagnetic spectrum 
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The speed of light in a vacuum is defined to be exactly 299,792,458 ms-1, 
approximately 186,282 miles per second (the meter is now defined in terms of 
the speed of light, hence approximate value in miles per second). All forms of 
electromagnetic radiation move at exactly this same speed in vacuum giving 
them wavelengths inversely proportional to their frequencies. In 1900 Max 
Planck suggested that although light was a wave, these waves could gain or 
lose energy only in finite amounts related to their frequency, known as quanta. 
In 1923 Arthur Holly Compton showed that the wavelength shift seen when low 
intensity X-rays scattered from electrons (Compton scattering) could be 
explained by a particle-theory of X-rays, but not a wave theory. Thus eventually 
light was described in terms of both a particle and a wave. Radio waves and X-
rays involved in Compton scattering tend to behave more like a classical wave 
at lower frequencies, but more like a classical particle at higher frequencies, but 
never completely loses all qualities of one or the other. 
EMR in the visible light region consists of photons capable of causing electronic 
excitation within molecules, which lead to changes in the molecular bonding or 
chemistry. At the lower end of the visible light spectrum, EMR becomes invisible 
to humans (infrared) because its photons no longer have enough individual 
energy to cause a lasting change in conformation in the visual molecule retinal 
in the human retina.  
 
2.3 Biological Diagnostics 
There are many radiological imaging techniques that aid clinician in making a 
diagnosis of an abnormality in the gut (computer tomography, barium enema, 
capsular endoscopy, magnetic resonance scan) however these do not allow 
concurrent tissue diagnosis and patients have to be brought back at another 
time to take biopsies of suspicious lesions.  Colonoscopy, as described in 
Chapter 1, remains a sensitive method of imaging the entire colon, with the 
benefit of tissue diagnosis and treatment with tissue resection in some 
instances, and is considered to be the Gold standard in ‘screening’ or detection 
tool. Colonoscopy enables the clinician to visualise pathology inside the gut and 
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to acquire tissue biopsies for further analysis at the same time. Further 
techniques such as tattooing are also available so that the area can be 
identified at a later stage, which make colonoscopy as a technique a very 
efficient process with satisfaction for the patient and clinician.  
The current gold standard for diagnosis of tissue abnormalities, specifically 
cancer and early change of cancer, remains with conventional histopathology.  
Specimens taken at colonoscopy; either whole polyps or in piecemeal are fixed 
in formalin and sent to histopathology lab for processing and assessment. This 
involves further tissue manipulation embedding it into paraffin, sectioning and 
then staining the sections of tissue. They can then be visualised by the 
pathologist using a microscope. This is a time-consuming process, and 
preparation is very dependent on the skill of the practitioner. The main problem 
with individuals reporting cases is the subjective nature of interpretation. There 
is often a degree of inter-observer disagreement(Lieberman et al. 2000; Turner 
et al. 2013) and this has proved to be an ongoing problem for clinicians to make 
an absolute, or definite diagnosis especially in some cases where several 
pathologies are very similar. Colonoscopy itself is considered to be a fairly low 
risk procedure- it is a day-case procedure in the UK and patients arrive at the 
hospital on the day of their procedure and go home the same day, all being 
well, with only a short period of monitoring necessary after (and this is often 
dependent on the sedation drugs used during the procedure). The main risks 
are either immediate risk to the patient of bleeding during the procedure and 
perforation (following polypectomy or biopsy during the procedure or from the 
scope passing around and tearing the bowel) although sometimes this is not 
diagnosed until after the procedure. Also very small polyps can go unnoticed by 
the clinician and these therefore do not get removed at the time but have the 
potential to develop into a cancer. Small flat (particularly right-sided) adenomas 
can be easily missed.(Horiuchi and Tanaka 2014) Delay in organisation of 
colonoscopy by department can cause patient distress, and incur high financial 
and resource costs to the hospital. 
There is therefore a real need for complimentary diagnostic technology during 
or adjunct to the colonoscopy procedure to help simplify and speed up 
diagnosis. In recent years several biophotonic diagnostic methods that are 
complementary to conventional histopathology have been developed to reduce 
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the subjectivity and invasiveness of diagnosis in the colon. A range of enhanced 
optical techniques have been developed to aid clinicians and pathologists in 
diagnosis and efficiency of routine clinical practise.  
These mostly aim to assist/ improve in one of the following four clinical areas;  
 greater polyp detection 
 optical biopsy 
 identification of flat dysplasia 
 risk stratification through field carcinogenesis detection.(Roy et al. 2011) 
 
2.4 Overview of Wide-field Imaging Techniques 
2.4.1 High definition white light endoscopy 
High definition white light colonoscopy is gradually replacing the traditional 
white light because the images are clearer and crisper and generally better 
quality. However there is no substantial evidence that this actually cause any 
improvement in adenoma detection rate- a large meta-analysis in 2011 
demonstrated only a 3.5% improvement in detection rate in the high definition 
group.(Subramanian et al. 2011) The equipment is more expensive and it has 
been difficult to justify rolling out the new high definition sets for little perceived 
gain, however often units are replacing their old scopes and stacks with the new 
technology as they become worn out and fail.  
 
2.4.2 Chromo-endoscopy 
Indigo carmine spraying of colonic mucosa through the instrument channel of 
the colonoscope increases the visual contrast between normal and abnormal 
mucosa and therefore makes it easier to pick up lesions than colonoscopy 
alone. It is a simple, safe technique that uses current colonoscopes. A 
randomised control trial in 2011 demonstrated an increased detection rate of 
adenomas in the chromo-endoscopy group as opposed to the white light 
colonoscopy, however it was noted to significantly increase the overall length of 
the procedure which was again, operator-dependent.(Pohl et al. 2011) It was 
noted to be helpful in visualising the boundary of a lesion and defining very 
small lesions better. However spraying of the entire colon was so time-
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consuming that it was thought to be impractical for everyday use. It was a 
technique particularly popular in the Far East as these clinicians have a lot of 
experience with the technique in the upper gastrointestinal tract.(Song et al. 
2007) A classification of polyps using a magnified view of the colonic crypts (up 
to x 100) and indigo carmine dye was developed called the Kudo classification. 
It divides polyp pit pattern into 6 categories which correlate to histological 
findings and help the operator to determine if a lesion is likely to be 
malignant.(Kudo et al. 1994; Liu et al. 2003) 
 
2.4.3 Virtual Chromo-endoscopy 
Narrow band imaging (NBI), I-Scan and Flexible Spectral Imaging Colour 
Enhancement (FICE) use optical/ electronic methods to gain more detailed 
mucosal surface information. NBI is a diagnostic imaging technique where the 
mucosal detail is enhanced by the application of blue and green light that is 
activated by a switch in the endoscope. These wavelength bands correlate to 
the peak light absorption by haemoglobin and therefore vessels containing 
blood appear darker. NBI allows the morphological and structural character of 
lesions to be examined in greater depth, including the pit pattern, without the 
need for dye. A comparison of techniques is seen in Figure 2.3, demonstrating 
an increase in degree of polyp surface detail obtained using carmine dye and 
NBI compared with simple white light colonoscopy. NBI has been shown to 
demonstrate a diagnostic accuracy of over 95% when comparing malignant and 
non-malignant lesions.(Sano et al. 2009) The pickup rate for abnormalities 
equals chromo-endoscopy, with the benefit of better visualisation of the 
vascular pattern, without the need for time-consuming spraying and no need for 
the dye itself. Based on colour, architecture, and pattern, NBI enables a more 
accurate diagnosis at time of colonoscopy without the use of dye.(Tanaka and 
Sano 2011) The NBI system is again based on the subjective judgement of the 
endoscopist, so recent research has been directed at developing an objective, 
in vivo real time diagnostic tool to distinguish adenoma from 
carcinoma.(Inomata et al. 2013) 
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Figure 2.3: Adenoma detection with (Left:) Simple white light 
colonoscopy, (Centre:) Carmine dye enhanced, and (Right:) narrow band 
imaging (Tanaka and Sano 2011) 
 
 2.4.4 Fluorescence spectroscopy 
Fluorescence spectroscopy as the name suggests, uses tissue fluorescence to 
differentiate tissue types. Fluorescence occurs when light (of specific 
wavelength for fluorophore) is directed onto a tissue; the light is absorbed and 
causes autofluorescence from endogenous molecules within such as collagen, 
elastin and various enzymes (the fluorophore). The ratio between incident light 
and fluorescence intensity can be used to discriminate various tissues 
depending on the content of endogenous fluorophores present.(Taylor et al. 
2007) It is also possible to use exogenous molecules, supplied either topically 
or systemically, which increase the production of fluorophores within abnormal 
tissue and enhance the contrast with normal tissue. It is particularly interesting 
and useful in areas of flat dysplasia, alone or within inflammatory pathology but 
there have been significant false positives with this. The majority of in vivo work 
by various groups has been done with laser-induced fluorescence spectroscopy 
(LIFS) either utilising natural fluorophores or exogenous drugs that target 
specific tissue. This is less favoured because of potential patient-drug 
interactions. LIFS to detect autofluorescence has been used successfully in 
brain, bladder and oral cavity but sensitivity has been unacceptably low with a 
significant number of false positives, particularly in the bladder.(Andersson-
Engels et al. 1990; Svanberg et al. 1994; Vo-Dinh et al. 1995) 
The difficulty over the last few years has been actually proving that these 
techniques significantly improve the detection of adenomas or diagnosis of 
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cancer. A randomised controlled study in 2011 combined high resolution 
endoscopy with NBI and AFI in a single endoscope called trimodal imaging 
(ETMI) and compared with standard video endoscopy. They were overall 
unable to improve adenoma detection rate although found ETMI was useful in 
discriminating adenomas from normal tissue.(Kuiper et al. 2011) Similar work 
has been replicated a number of times and only minimal improvement has been 
demonstrated. Consequently in most hospitals these techniques are only 
employed by clinicians specially trained or dealing with particularly high risk 
surveillance groups. In the last few years, a team at Washington State 
University has been developing the use of real time intra-operative near-infrared 
fluorescence goggles. The patient is injected with indocyanine green which is 
taken up by the tumour cells pre-operatively and the surgeon wears the goggles 
during the procedure to aid the removal of the whole of the tumour (a benefit 
when the edges are not well demarcated). The research was first trialled in rat 
models but is now in human trials phase and hit the newspaper headlines 
earlier on in the year.(Liu et al. 2013; BBC Health 2014) This technology could 
potentially be applied for use during colonoscopy for real-time tumour diagnosis 
and margin assessment during polypectomy, however it does not currently 
confer the subtlety needed to differentiate between similar pathologies in the 
gut. 
 
2.5 Point Measurement Techniques 
2.5.1 Confocal Fluorescence microscopy 
Confocal microscopy is a non-invasive method of optical imaging in two 
different ways; reflectance, based on the difference in refraction of cellular 
tissue structures and fluorescence, based on natural fluorophores in the tissue, 
both in vivo and in vitro.(Ragazzi et al. 2014) An image is formed by detection of 
high-resolution fluorescence generated from a scanning laser beam, providing 
optical slices through the sample and creating a 3 dimensional image when a 
whole stack of these are obtained. Keisslich et al. performed the first colonic 
studies and used fluorescent agents to obtain images with a sensitivity of 97% 
and accuracy of 99% when compared with histological assessment.(Kiesslich et 
al. 2004) However the need for an exogenous fluorophore made this unpopular 
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and experimental difficulties were found with peristalsis of the gut and debris 
interfering with the signal. 
 
2.5.2 Light scattering spectroscopy 
Light scattering spectroscopy is based on the elastic scattering of light (without 
a change in energy level). Tissue pathologies are detected and diagnosed using 
spectral measurements of the elastically scattered light, in a manner that is 
sensitive to both scattering and absorption properties of the tissue, over a wide 
range of wavelengths.(Mourant et al. 1996) Particles scatter light best when the 
wavenumber approaches their own size; neoplastic tissues have increasingly 
large amounts of nuclei and mitochondria when compared with normal so the 
elastic scattering is of a longer wavelength.   A study in 2006 by Dhar et al. 
used the technique with an in vivo probe and found the technique to be 
promising in the differentiation of normal, inflammatory and neoplastic tissue. 
The aim was to develop a real-time diagnostic implement that could potentially 
reduce the unnecessary removal of certain polyps and therefore minimise the 
risk to the patient, the results however, were not found to be particularly 
sensitive.(Dhar et al. 2006) 
 
2.5.3 Optical Coherence Tomography 
This is a non-invasive imaging technique that relies on light scattered by the 
sample and subsequent interference, and provides a cross sectional image of 
the tissue(Fujimoto et al. 1995) an example of which can be seen in Figure 2.4. 
Light is reflected from surface tissue microstructures and detected to a spatial 
resolution of 4-20 µm.(Sivak et al. 2000) The resolution is many more times 
greater than ultrasonography, an analogous technique, and so the images 
created are much more detailed, and based on cellular architecture rather than 
tissue structure. Visual inspection of OCT images can be used to assess tissue 
morphology, and to differentiate between normal and abnormal tissue 
types.(Gossage et al. 2003) 
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Figure 2.4: An example of Optical Coherence Tomography used to 
examine the retina of the eye in detail(Eye Site Texas 2015) 
 
Studies have combined the use of Raman and OCT as a useful tool for tissue 
diagnosis combining the molecular and topographical information obtained. 
Ashok et al. combined the two in comparison of normal and cancerous colonic 
tissue in vitro and found that the combined approach improved sensitivity of 
detection from 77 and 74% respectively to 94%.(Ashok et al. 2013) However 
the technique is limited by depth of investigation and so its use for real-time 
diagnosis is limited because of this in colonoscopy, other than perhaps to 
assess the depth of tumour invasion through the muscularis mucosa, which 
may help staging for cancer. It is also a very time-consuming technique 
because of the length needed for image acquisition and operator dependent. 
 
2.6 Biospectroscopy 
Infrared (IR) and Raman spectroscopy are techniques used to interrogate 
biological tissues in order to understand the changes in the molecular 
constituents that are associated with cancer progression from normal to 
malignant. These spectroscopic techniques have the ability to provide detailed 
biochemical information since the spectrum obtained from cellular tissue 
measurements are intrinsic molecular fingerprint of the sample that reveals 
information about the DNA, carbohydrate, protein and lipid content.(Chan et al. 
2006)  Each spectrum is made up of varying contributions from many molecular 
bond vibrations and is therefore a superposition of all constituents in the 
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measured sample which therefore contains potentially useful biodiagnostic 
information.(Naumann 2008)  
2.6.1 Raman Spectroscopy 
Raman spectroscopy is the measurement of inelastically scattered light. It 
requires monochromatic irradiation and detects a scattering pattern from the 
excitation of molecules.(Lyng et al. 2015) White light incident upon a specimen 
may be altered in wavelength and this can be measured and represented as a 
Raman spectrum. This can provide a unique biochemical ‘fingerprint’ of the 
sample.(Kendall et al. 2009) The largest and most recent Raman study in the 
colon was by Wood et al. in 2014; a modified confocal Raman probe was used 
to differentiate cancer, inflamed and normal tissue with a sensitivity of over 
75%.(Wood et al. 2014) There is huge precedence of the use of Raman probes 
in vivo in the oesophagus, where a variety of different probes with different 
design in different tissues have been used.(Almond 2012; Kallaway et al. 2013) 
Future work needs to be performed to use the Raman probe in vivo in the colon 
at time of colonoscopy to make real-time diagnosis, particularly of microscopic 
colitis which could lead immediate treatment for the patient. 
 
2.6.2 Infrared Spectroscopy 
Infrared spectroscopy is the absorption of photons detected when molecules in 
a substrate are irradiated with polychromatic mid-infrared light. In this study we 
propose to use infrared spectroscopic analysis of colon cells to aid the difficult 
diagnosis of epithelial misplacement and attempt to streamline the diagnosis of 
cancer. 
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CHAPTER 3 
INFRARED SPECTROSCOPY 
 
Infrared (IR) radiation spans an interval of the electromagnetic spectrum 
between the red end of the visible region (wavelength ~780 nm, frequency 
~3.8x1014 Hz) and the beginning of the microwaves region (1 mm, 3x1011 Hz). 
The infrared band can be split into: 
 Near – IR (from ~780 nm to 2.5 µm) 
 Mid – IR (from 2.5 to 25 µm) 
 Far – IR (from 25 to 1000 µm) 
Within the infrared band, the light waves vibrate at varying frequencies, which is 
inversely proportional to (sinusoidal) wavelength, λ, when c is constant speed 
(phase speed of the wave): 
λ = c / v 
 And the most commonly used spectroscopic unit in the IR region is the 
reciprocal of the wavelength, 1/λ, called the wavenumber. 
Molecular vibrations can be excited by the absorption of light.(Herzberg 1950) 
When infrared incident light is shone on a tissue, the molecules absorb photons 
which results in change in the vibrational mode. A molecular vibration occurs 
when atoms in a molecule are in motion, while the molecule as a whole is also 
in motion (translation and rotation). The frequency of the atomic motion is the 
vibrational frequency. A molecular vibration is excited when the molecule 
absorbs a quantum of energy, E, corresponding to vibrational frequency, v: 
E = hv  (h is Planck’s constant) 
When a sample is placed in the path of an IR beam between the source and the 
detector, the molecule will absorb the frequency of IR that coincides with the 
frequency of vibration that the molecule enters in a resonant vibrational state. 
The change in energy through absorption alters the dipole moment of the 
molecule, thus the charge distribution of the molecule is changed.  
Page | 51 
 
 
3.1 Vibrational Modes 
Atoms in a molecule are constantly moving while the whole molecule 
experiences continuous translational and rotational movement. A molecule with 
two atoms has just a single motion, but molecules with any number of atoms 
have more than one type of vibration, or mode. 
The vibration of molecules detected by IR spectroscopy is determined by the 
number and type of bond movements. IR spectroscopy detects changes in the 
permanent dipole (not molecules with only two atoms, unless they are 
asymmetric e.g. CN, because they only have one bond and therefore one single 
vibration). Polyatomic molecules have several normal modes of vibration which 
include: asymmetric, symmetric, twisting, scissoring, rocking and wagging, as 
seen below in Figure 3.1. The number of vibrational modes for a non-linear 
molecule is described as 3N-6, where 3N is the 3-dimensional movement 
around N atoms (or ions), and -6, rotational motions around 3 axes. 
 
 
 + Above the plane    – Below the plane  
 
   Scissoring          Rocking                   Wagging             Twisting 
          In-plane Bending                       Out-of-plane bending 
Figure 3.1: Variations of molecular bond movements 
  
 
  
 
  
 
  
 
+ + + _ 
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A water molecule, H-O-H, for example, exhibits asymmetric and symmetric 
stretching and bending vibrations at ~3500 cm-1, ~1650 cm-1 and 600 cm-1. 
Carbon dioxide, 0-C-0, is detected at ~2560 cm-1 (asymmetric) and ~500 cm-1 
(scissoring bending).  
IR spectroscopy therefore essentially measures the loss of radiation transmitted 
through a sample. The intensity of absorption bands can be plotted against 
interval of wavenumbers, which corresponds to changes of vibrational energy 
levels from the ground level to the first energy level in molecules 
(E0→E1)(Bellisola and Sorio 2012). The intensity in peaks reflects the amount of 
different molecular bands absorbing specific regions of the IR spectrum. 
Frequencies at which absorption at specific vibrations occur are fairly constant 
and can therefore be reproducibly detected within a sample, see Figure 3.2.  
 
 
 
Figure 3.2: An example of infrared absorption peaks and the molecular 
bond attributed to water and carbon dioxide(The Earth Observatory 2014) 
 
3.2 Clinical Need for Infrared Spectroscopy 
Infrared (IR) spectroscopy offers the advantage of being able to perform the 
technique on samples routinely processed by the histopathology labs. Its use is 
more limited in fresh samples because of the presence of water molecules in 
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the tissue which are identified very readily in the IR spectra to the cost of other 
information. This limits the use of IR for real-time, however it is the ideal 
investigative tool for analysis of formalin-fixed, paraffin embedded specimens. 
This also confers the added benefit of multiple measurements from the same 
sample because there is no concern that the fixed sample will dry out, as is the 
case when analysing fresh samples. The water signal is also reduced in the 
processing of fixing so the noise is reduced. Until recently however, the paraffin 
signal was often very marked in results and made computer analysis of the 
spectra complicated. Cluster analysis is for example, very influenced by the 
presence of paraffin signal and can affect interpretation of the results.(Hafiane 
et al. 2008) However recent advances in computer programming have enabled 
the paraffin signal to be counteracted at the pre-processing stage; numerical 
techniques applied directly to the spectral map, rather than chemical 
deparaffinisation (thus simplifying the experimental protocol)(Nallala et al. 2012) 
which has made the analysis of spectra produced with this technique easier and 
more streamlined. It also enables samples taken during routine clinical 
assessment such as polyps at colonoscopy which are then sent for routine 
processing, to be analysed by IR spectroscopy. This creates a huge potential 
wealth of samples that can be analysed from historical record and with little 
need for further processing or need to collect more samples. There is no 
evidence to suggest that age of paraffin-embedded specimen affects results, so 
the potential role for identifying historical samples from tissue BioBank and 
Pathology departments is huge. IR spectroscopy is a technique that therefore 
lends itself to in-depth analysis of historical samples without further need for 
processing, and as such the technique is highly applicable for use with routine 
processing methodology in place within the NHS. For these reasons it was 
decided that analysis IR spectroscopy would be the optimum technique for 
analysis of historical EM samples.  
 
3.3 A Historical Overview of infrared Spectroscopy 
Infrared spectroscopy (IR) provides, in a non-destructive and label-free manner, 
a biochemical fingerprint of cells and tissues.(Martin et al. 2010) A spectral map 
is created, where each pixel of the image provides a complete spectrum across 
the wavenumbers(Lasch et al. 2004). This information obtained from a sample 
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offers insight into the presence of particular molecules and their structure and 
metabolism. This is of particular relevance and interest when monitoring 
molecular change in early disease such as the change from high grade 
dysplasia to invasive carcinoma. The technique, coupled with microscopy has 
been recognised since the mid- 20th century. However it wasn’t until the late 
1970s that commercially driven IR spectrometers were introduced. It gained 
popularity through its use of trace samples which did not get destroyed during 
measurements and required minimal sample preparation; results were frequent, 
precise and reproducible.(Bellisola and Sorio 2012) Combined with a Fourier 
Transform technique (a mathematical process which allows simultaneous 
collection of the full spectral range and converts raw data into the actual 
spectrum) and appropriate statistical data analysis methods, IR spectroscopy 
has been used over the decades as a helpful diagnostic tool in various organs 
including breast,(Rehman et al. 2010) oesophagus,(Quaroni and Casson 2009) 
colon,(Rigas et al. 1990) liver,(Le Naour et al. 2009) and lymph system.(Bird et 
al. 2008)  
 
3.4 Applications of Infrared Spectroscopy 
Rigas et al. demonstrated a difference in FTIR signal between normal and 
cancerous fresh tissue from the same surgically resected colon in 11 
patients.(Rigas et al. 1990) Each tissue section was compared with stained 
H&E slide and examined by two blinded pathologists. Data was presented as a 
description of the change in the bands between normal and cancerous tissue, 
but there was evidence of significant inter-patient variability with such small 
sample numbers. They noted a change in the intensity of bands at certain 
wavenumbers, particularly those corresponding to phosphate and nucleic acid 
bands, and particularly noted a shift in the peak maximum of the bands and 
their centre of gravity, but no attempt was made at complex analysis further 
than band observations. Argov et al. were the first group to publish a direct 
comparison of normal and cancer spectra with those of polypoid lesions in three 
patients.(Argov et al. 2002) They postulated that the FTIR signal should 
demonstrate the changing biochemistry of early neoplastic change in 
adenomas. The total number of patients was included was 24, so more 
inclusive of population variation than the Rigas paper. They used 128 scans 
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and generated a total of 300 spectra for analysis. Spectral analysis was also 
more complex and was performed using an artificial neuronal network (ANN) to 
generate a prediction model and compare morphological differences between 
specimens. Peak analysis was performed on only 3 patients; RNA/ DNA ratio 
was found to increase with malignancy but was a poor discriminator of normal 
and adenomatous tissue, however by contrast levels of carbohydrate were 
higher in normal than for malignant tissue. The ANN classified 24 tissue types 
based on 5 features resulting in a sensitivity of 81-89% across the pathology 
groups, however specificity was lower.  
Li et al. performed in vivo studies on colon in 2005 with the potential of 
assessing resection margins intra-operatively or real time pathological 
diagnosis.(Li et al. 2005) A small number of cases were included, total from five 
patients were included although one of these was rectal. They used fibre-optic 
attenuated total reflectance (ATR) FTIR spectroscopy in vivo and in situ intra-
operatively to measure spectra on the surface of diseased tissue with a reading 
from normal tissue close by. The rectal tissue was actually measured pre-
operatively with the patient awake, taking a minute in total to acquire 32 scans. 
Analysis was descriptive of the change in bands between normal and 
cancerous tissue, particularly of carbonyl, methyl and methylene (reduced in 
cancer presumably because of higher energy requirements in the cancerous 
tissue using local triglycerides which contain these specific groups) and all 
spectra correlated with histopathological result for the each patient. No attempt 
at more complex analysis was made however, and these results although 
promising, are limited due to lack of case numbers and therefore total number 
of spectra, variation in population and assumptions made about peak 
assignments without quantifying the data further. 
Techniques for demonstrating the success of IR spectroscopy gathered 
particular momentum as a diagnostic tool in the following few years.(Krafft et al. 
2009) Lasch et al. used FTIR spectroscopy to map one case of rectal 
carcinoma using fresh frozen tissue and compared a number of unsupervised 
analysis techniques.(Lasch et al. 2004) They produced a variety of false colour 
maps of a section of cancerous tissue and compared the images for a number 
of different computer techniques, which is a much more robust way of analysing 
the spectra than simply peak assignments. They obtained very clear images 
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from the three techniques and showed that this new technology could produce 
images with much more detailed spatial information present comparable to 
traditional pathology stains from which diagnosis could be achieved. Various 
statistical analyses began to be applied to tissue maps to increase the contrast 
between tissue structures in normal and cancerous tissues.(Kendall et al. 2009) 
Once the maps had been processed with multivariate statistical approaches, 
biomolecular information could be compared between normal and abnormal and 
the presence of tumour or inflammation in the tissue identified.(Wood et al. 
2011) As such, two years after their initial results series Lasch et al. published 
similar work with supervised analysis techniques to identify great detail within 
the tissue sample, including neoplastic epithelium, necrotic areas of tumour and 
mucin.(Lasch et al. 2006)  
Krafft et al. also produced FTIR microscopic images and compared them with 
those acquired from Raman spectroscopic imaging.(Krafft et al. 2008) They 
used a single colon specimen and snap froze the acquired tissue to analyse via 
the two methods. Three distinct tissue regions were compared using the two 
techniques and unsupervised k-means cluster analysis applied to segment the 
data sets, although the cluster assignments were not then evaluated for 
accuracy by a pathologist for Gold Standard of assessment. They assigned the 
clusters to various histological structures and were able to favourably compare 
Raman and IR for specific areas of tissue. Peak assignments of the clusters 
were analysed for spectral differences and described for the proposed 
histological areas.  
Conti et al. compared healthy and cancerous colon tissue on formalin-fixed, 
paraffin-embedded using near infrared FTIR microspectroscopy.(Conti et al. 
2008) They collected a bigger dataset of 1269 spectra of unknown number of 
patients at a resolution of 50 x 50µm in reflection mode. Band assignment was 
carried out in accordance with data from the literature with a change in intensity 
and shift of some significant peaks. Multi-variant statistical analysis was 
performed before creation of topographical custom colour maps using the 
spectra loaded onto a chemical map.  They were confident that these colour 
maps represented the corresponding pathology on H&E slide. Ultimately a 
number of ‘spectral patterns’ were suggested to be able to distinguish normal 
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from cancerous tissue, however there was no statistical evaluation of these 
suggestions. 
A large study was performed by Zweilly et al. comparing the spectra of 240 
patients across 5 groups which included normal, cancer and adenoma with 
varying grades of dysplasia.(Zwielly et al. 2010) They also found differences in 
peaks at various wavenumbers which could be assigned to specific molecules 
and postulated that lipid/protein ratio increases with increasing severity of 
disease, and phosphate levels were lower reflecting the high metabolic turnover 
in malignant tissue. Cohenford et al. also performed FTIR spectroscopy on 
fresh frozen tissue from specially bred mouse colons and cell lines.(Cohenford 
et al. 2012) Classic spectral analysis of band peak intensity ratios, areas, and 
shifts in spectral peaks were compared for over 700 sites from 10 mice, as well 
as subtle differences between the spectra detected with multivariate statistical 
analysis. In-keeping with previous studies they found a statistically significant 
difference between the mean and SDs of amide II/I ratios in normal colon cells 
and in colon cells with high-grade dysplasia, suggestive of a variable amount of 
DNA, assigned to the high turnover associated with malignancy. Statistical 
analysis was very successful with a sensitivity of 91.4-100% and specificity of 
94.1-100%. Misclassified spectra were low. Whether or not these results would 
be replicable in human tissue however remains to be seen. 
Later experiments focused on the use of multivariate spectral analysis in 
various forms to analyse results and display subtle differences between 
pathological groups. Wood et al. performed FTIR spectroscopy and mapping 
across a range of colonic pathologies for the first time, including results from 
areas of inflammation in diseases such as ulcerative colitis.(Wood et al. 2011) 
This was also the largest study with regards to number of spectra to date (6944 
from 10 samples). A 2-dimensional plot of the groups was constructed to map 
findings over the white light image and PCA-fed LDA and cross validation 
methods performed to assess the accuracy of the classification model. 
Prediction accuracy varied from a sensitivity of 91.6% to 100% and a specificity 
of 97.7 to 99.9%. Ordinary least squares relative signal contributions to tissue 
spectra were demonstrated following analysis of first derivative spectra to 
explain the biochemical basis of the accuracy of the model.  
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Kallenbach-Thieltges et al. used FTIR in conjunction with regular 
immunohistochemistry and fluorescence to automatically identify colon tissue 
types known as Spectral Histopathology (SPH).(Kallenbach-Thieltges et al. 
2013) Good correlation between the techniques was found to ascertain the 
morphology of the tissues and several distinct structures and tissue types 
(lamina propria, muscularis mucosa etc.), and comparison made with traditional 
H & E reviewed by an expert pathologist. The accuracy of the Random Forrest 
statistical analysis method used was found to be around 95%.  
Nallala et al. used FTIR spectroscopy to generate a new concept in analysis 
called spectral barcodes.(Nallala et al. 2013)  IR images from 10 patients, 
cancer and normal, were clustered and classified according to their 
biochemistry to produce colour-coded images. These cluster images enabled 
the retrieval of specific IR signatures to differentiate cases of cancer and non-
cancer epithelial components. Statistical analysis was performed on the specific 
signatures to identify the most discriminate wavenumbers from the two tissues 
and arranged in the form of spectral barcodes. 
 
3.5 Infrared Spectroscopy Instrumentation and Set-up 
FTIR spectroscopy uses the mid-infrared region of the EM spectrum and 
studies the interaction of infrared light with a sample. The typical pathway is 
described in Figure 3.3.  
FTIR spectrometers use a light source where the light passes through an 
interferometer to provide an interferogram, which is the inverse Fourier 
transform of the spectrum.  The interferometer allows the whole range of 
wavelengths of light to be measured at any one time, thus reducing the time 
taken to scan dramatically. Light is directed towards a specimen and absorbed 
at the frequency at which the incident radiation is equal to that molecule’s 
vibrational mode. This loss is detected against the background at each 
frequency in the spectrum.  
After light passes via a series of reflective optics through the specimen, the 
interferogram is scanned through using a moving mirror in the reference arm of 
the interferometer. The signal  is measured with a single detector.(Kendall et al. 
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2009) The computer is then used to perform a Fourier transform on the data to 
convert it into a transmission spectrum (Barth 2007) (other modes are available 
such as reflectance, when reflected radiation from the specimen surface is 
measured). The ratio of the sample transmission spectrum to the background 
transmission spectrum provides the transmittance spectrum of the sample 
(removing the instrumental contributions to the spectrum). 
A transmittance spectrum is the transmittance plotted against wavenumber. If 
all light passes through a sample then the transmission is 100% and 
absorbance zero and vice versa to varying degree.  An absorbance spectrum is 
generated from logarithm to the base 10 of the reciprocal of the transmittance. 
 
 
Figure 3.3: Schematic simplified representation of the basic components 
of an infrared spectrometer 
 
Infrared systems have the following similarities; they are equipped with a 
microscope coupled to a light source, a computer and often have a sensitive 
liquid nitrogen cooled Focal Plane Array (FPA) detector, which if present 
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requires cooling to 77K. Liquid nitrogen is poured into a dewar for storage, and 
gradually the detector temperature reduces. This remains cool for a period of 
approximately 6 hours for both. Before any measurements are taken the user 
must ensure that the detector is cool enough and energy reading is appropriate.  
 
3.6 High Resolution Infrared Spectroscopy 
The University of Exeter houses one of only a few novel ‘high resolution’ 
spectrometers in the world. It is a prototype system developed by Agilent® with 
a high magnification optical system. The main differences between high and 
standard resolution are the optics- the high resolution optics have an additional 
magnifying element in combination with a high numerical aperture 15 x 
condenser. Together these give 40 x magnification (1.1 µm) compared with 
standard 15 x (5.5 µm) pixel size. This therefore has the potential to differentiate 
smaller features (potentially sub-organelle) and thus give greater amount of 
information per pixel which could increase the heterogeneity of data collected.  
The understanding of this new technology is still in evolution, and as a 
consequence there is very little published data on this new technology. The 
University of Exeter team is one of a number of research centres involved in the 
Minerva® (MId- to NEaR infrared spectroscopy for improVed medical 
diAgnostics) project which is supported by the European Commission under the 
Seventh Framework Programme (FP7).(Napier 2012) This project aims to 
provide high resolution and tunable IR imaging so that specific spectral regions 
of interest can be selected to allow rapid imaging in the future. Consequently 
the set-up parameters of the experiments in this thesis, such as number of 
scans per sample, were therefore directed by the team based on as yet 
unpublished work from them. The first published high resolution data was in 
2012 testing accuracy of the technique using brain tissue and Arctic Sea Ice 
Diatoms in comparison to standard resolution and Synchrotron light source. 
They found an increase in spatial and spectral detail, particularly in the 
fingerprint region, of comparable quality for signal to noise ratio in formalin fixed 
paraffin embedded tissue. Results were obtained using only a cheap bench top 
light source.(Findlay et al. 2015) 128 scans and a resolution of 4 cm-1 were 
used with samples mounted on barium fluoride slides, but only one case of 
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human tissue was analysed. A recent paper demonstrates the use of high-
resolution spectroscopy at comparable magnification to the experiments in this 
thesis on both kidney and liver tissue, but focused on presentation and 
comparison with standard resolution rather than building a model for tissue 
classification as has been done in this thesis, and only a few pathological cases 
were actually analysed.(Sreedhar et al. 2015) Another team focused their 
experiments on the theory of light interaction at a reduced pixel size and 
calculated the smallest functioning aperture size to produce a pixel size of near 
1.1 µm (128 scans at resolution of 8 cm-1). Again this was presented in a format 
of comparison against the standard resolution using prostate tissue, rather than 
as a case series with analysis as in this thesis. They found that the smaller pixel 
size gave much more detail in the resulting images but at the expense of lower 
signal to noise ratio and proposed a computational method of noise reduction 
without increasing experiment time.(Reddy et al. 2013) 
 
3.7 Thesis Objectives 
The aim of this study is therefore to use high-resolution infrared spectroscopy to 
interrogate colonic tissue and analyse the resulting spectra. The benign 
pathological condition of epithelial misplacement and the difficulty associated 
with its diagnosis has been discussed at length in this thesis and it is here that I 
will focus my research as there is a clear clinical need for improvement in its 
diagnosis. 
I will therefore attempt to use high resolution infrared spectroscopy to 
differentiate normal colonic epithelium from a range of common colonic 
pathologies that would be readily found at polypectomy and biopsy during 
BCSP colonoscopy, with particular interest in the use of infrared in the 
differentiation of cancer from epithelial misplacement. 
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CHAPTER 4 
MATERIALS AND METHODOLOGY 
 
4.1 Ethical Approval 
Ethical approval for the project was granted by Gloucestershire Local Ethics 
Committee and was already in place at the beginning of the project. Those 
patients eligible for participation within the study were identified from historical 
hospital databases. No fresh tissue was collected for this particular project and 
so it was not necessary to consent the patients for tissue use. 
 
4.2 Tissue Collection 
Patients were identified from hospital databases where all pathology specimens 
are given a unique code from hospital records. Specific cases of epithelial 
misplacement and polyp cancer were identified by records kept by Professor N 
A Shepherd in his capacity as Regional and Local BCSP Pathology Lead. 
Once the specific cases had been identified, the histology case number was 
identified from the patient number, and this was used to track the location of the 
tissue in storage. The historical cases had already been previously routinely 
processed and placed in formalin at time of excision and original investigations 
and then embedded by the Histopathology laboratory. All tissue had been kept 
in ideal conditions according to departmental protocol. Thus the paraffin 
embedded tissue blocks had to be identified for each case. 
 
4.3 Histopathology 
Routine processing had been carried out for all specimens used in this project. 
Historical samples from 2010 onwards were used (from the end of the last PhD 
student so that no cases were overlapping and all work was original). 
Specimens were received by the histopathology laboratory fixed in formalin and 
examined macroscopically before being processed in cassettes and then put 
into hot paraffin wax to further fix and protect the tissue. Once the blocks had 
cooled and solidified they were then cut into 4 µm to 5 µm sections and placed 
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onto rectangular glass slides and undergo special H&E stain and 
immunohistochemistry to facilitate analysis under the microscope. All the cases 
had been reported by a Consultant Histopathologist and all abnormal results 
discussed at the Colorectal Multidisciplinary Team meeting (MDT). 
Pathology cases collected for this project included the following: 
1. Normal 
2. Adenomas (low Grade dysplasia) 
3. Cancers 
4. Polyps with Epithelial Misplacement 
5. Polyp Cancers 
A secure database was designed to store patient details including hospital 
number, date of birth, time of biopsy, and the corresponding sample details 
such as research code and histopathology details. Each patient was assigned a 
unique identification code according to group. 
 
4.3.1 Tissue Samples 
100 cases were initially identified in total across the five pathology groups, 20 
patients in each group. Historical samples were identified from June 2010 to 
May 2014. All these patients were managed according to the NHS protocols in 
place at the time. This research has not altered the management of any of the 
patients in any way. Some underwent surgery and further treatment at the time 
of their diagnosis and a few are still in follow-up programmes now. 
Acquisition of specimens took place in the histopathology laboratory at 
Cheltenham General Hospital between April 2014 and June 2014. Once the 
tissue blocks had been identified and found, the blocks had to be further 
sectioned for the number of experiments necessary by laboratory technicians at 
Gloucestershire Cellular Pathology Laboratory.  
The pathological diagnosis had already been made by one (or more – at this 
time, protocols were in place that assured that all diagnoses of cancer, whether 
in a polyp or otherwise, were confirmed by two consultant pathologists in 
Gloucestershire) Consultant as per routine processing protocols at the 
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Gloucestershire Cellular Pathology Laboratory in Cheltenham General Hospital. 
The reporting Consultant was not always the same person each time as cases 
are randomly allocated to Histopathology Consultants as part of their normal 
working day but each cancer diagnosis was confirmed independently by two 
consultant pathologists.  
A list of historical patient diagnoses for every biopsy and tissue sample taken is 
kept on record by the Trust in the coding department. This information was 
accessed to identify the cases across the five groups initially. Once the list of 
cases had been identified, the H&E slide and block were retrieved for all. A 
single expert gastrointestinal Pathology Consultant (NAS) then reviewed all 
H&E slides to confirm the diagnosis made previously. Any cases with a 
questionable diagnosis or when the two consultants differed in opinion were 
excluded from the experimental protocol. 
All cases of the cancer and epithelial misplacement (EM) had also been 
discussed at the local Hospital Colorectal multi-disciplinary team (MDT) meeting 
amongst a panel of expert Pathologists, Surgeons and Gastroenterologists, and 
management decisions made in advance of experiments being performed on 
remaining tissue. 
All cases of dysplasia used were classified as low grade. All cancers were 
classified as at least T2/3, the polyp cancers all being T1. 
Blocks were cut in contiguous sections of 5µm thickness and placed on slides 
as follows, see Figure 4.1: 
 
 H&E (glass) 
 IR slide (Calcium fluoride) 
 H&E (glass) 
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Figure 4.1: Schematic representation of sections through the tissue block 
 
An H&E was requested after every IR slide so that it could be ensured the 
pathology was visualised right through the 15µm thickness. This validated our 
sampling methodology and ensured that the pathology could still be found in 
latter sections. They were sectioned in continuity for the same reason which 
created a stack of contiguous sections. Every single slide was re-analysed by a 
specialist Consultant Histopathologist to ensure agreement with the initial 
diagnosis that had been recorded. Following analysis by the lead pathologist, 
several cases were deemed unsuitable or the pathology had been recorded 
incorrectly and so these were excluded. 
67 cases in total were identified which met all the criteria. Their corresponding 
tissue blocks were then sent to the Histopathology laboratory for cutting 
according to the experimental protocol. This resulted in a selection of new 
stained H&E slides for each sample with corresponding colourless Calcium 
fluoride (CaF2) slide sample (contiguous slides). On several occasions, more 
than one polyp was retrieved per patient, so the actual number of experimental 
cases was greater than total number of patients involved. A final total of 58 
patients were included in the study, see Table 4.1. 
 
 
 
 
 
 
 
 Remaining 
Block 
 
 
H&E 
CaF2 
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Group Normal Dysplasia Cancer Polyp 
cancer 
Epithelial 
misplacement 
Patient 
total 
12 10 8 13 15 
Sample 
total 
15 16 8 13 15 
Table 4.1: Initial total number of patient and study samples for each of the 
five pathological groups 
 
Calcium fluoride (CaF2) was used as the infrared slide substrate because it 
does not give any signal which can interfere with the fingerprint region (1000-
1800 cm-1 in infrared), see Figure 4.2 for the absorption spectra, whereas 
other substrates such as glass can prevent mid-IR transmission, since tissue 
absorptions below 2000 cm-1 are obscured by the opacity of glass. CaF2 
slides are comparatively expensive however, and great care was taken 
during handling to ensure that none were broken. 
 
 
 
Figure 4.2: Calcium fluoride slide absorbance signal(Davis 2007) 
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The slides were all labelled and correlated with the specimen database so 
that a clear record of each sample and its history was kept. The slides and 
remaining blocks were able to be stored at room temperature under normal 
conditions. No special provision had to be made during storage or at the time 
of IR spectroscopic analysis. They were all stored together in pathology 
cardboard folders which protected them from scratching and other sources of 
physical damage however did not completely protect from microscopic dust 
and particles. The slides were not fixed in place so transport was difficult and 
all folders had to be kept upright at all times. 
 
4.3.2 Image creation 
For every experimental sample, a white light image of the corresponding H&E 
stained slide was carefully mapped, digitally recorded and transferred for 
printing on A4 paper. This allowed the specific pathology to be identified and 
recorded in colour- something that was not possible with just the CaF2 slide. 
Because the slides were contiguous the H&E was accepted as a fair 
representation of the CaF2 sample for comparison.  
 
 
 
 
 
 
 
Figure 4.3: Histological H&E slide of normal glands (left), marked by 
pathologist with a circle, with corresponding white light image (right) 
 
It was very important to accurately record the exact location of these glands 
within the tissue on the slide so that they could be re-located at a later date for 
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infrared analysis. For each sample therefore, a hand drawn map of exact area 
and location was recorded, using structural tissue landmarks and local features 
to use at a later date. 
The expert pathologist was then able to manually select the exact glands 
required which ensured the quality of the selected glands. In many samples 
there was evidence of a heterogeneous population of glands within one 
specimen, and more than one pathology was noted to be present across the 
sample, for example the presence of both normal and dysplastic glands next to 
each other on one slide coded as dysplasia. The ability to identify and record 
the exact glands enabled the reviewing pathologist to be very precise.  It was at 
this point that it was realised that often there was more than polyp section on 
the H&E slide, and this did not always correspond with the specimen on the 
CaF2 slide, so a number had to be reprocessed to ensure that the glands could 
be identified on both the H&E and corresponding CaF2 slide. 
These reference maps were invaluable when it came to switching between the 
colourful stained slides to colourless unstained ones, and were particularly 
useful in areas with difficult merging glands where discrimination of one area 
from another was very difficult under the microscope.  
 
4.4 Infrared Measurements 
Experiments were conducted across the dataset over a period of 8 months from 
June 2014 to February 2015 and not in group order, to ensure that results were 
not skewed by experimental conditions on a particular day. 
Infrared experiments were conducted across two sites, initially at the 
Biophotonics Department at Gloucestershire Royal Hospital where a small 
number of cases were analysed at standard magnification and then at high 
magnification (see Section 3.6) in the Physics Department at the University of 
Exeter, Streatham Campus, between June 2014 and February 2015. Please 
see Appendix 1 for preliminary work completed on a minimal dataset on the 
standard resolution FTIR spectrometer at the Biophotonics Department in 
Gloucester. All experiments were conducted in purpose built rooms and in 
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accordance with safety guidelines with local risk assessment documents in 
place. 
Initial measurements were taken in Leadon House in the Biophotonics 
Department at Gloucestershire Royal Hospital, Gloucester. Two measurements 
per pathology group were taken in Gloucester to standardise and perfect the 
protocol. All other measurements for all samples were taken at the University of 
Exeter, Exeter in the Physics Department. Infrared map measurements were 
collected in Gloucester using a PerkinElmer® Spectrum One (Spotlight) 400 
Fourier transform infrared (FTIR) spectrometer (PE system) and at Exeter using 
an Agilent® 620 FTIR microscope coupled to 670 Agilent spectrometer both in 
transmission mode.  
The PE system provides 6:1 imaging, resulting in a pixel size of 6.25µm. A 
charge couple device (CCD) camera under white light LED illumination attached 
to the microscope and computerized x-y-z stage enable the specimen to be 
visualised and to capture a visible white light image. When the system is started 
up it checks that each component (stage controller, computer, microscope 
components, and Spectrum One) is attached and communicating well. 
Problems are highlighted on the panel of Spectrum One (each component must 
have a green light to start). The detector moves in a raster formation and 
collects 16 pixels at a time, see Figure 4.4. 
 
 
Figure 4.4: Schematic representation of Perkin-Elmer® detector raster 
movement. Each coloured dot represents the acquisition of a pixel (16 in 
total) 
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In contrast to the PE system, the Agilent, when set to high-resolution mode, has 
a pixel size of 1.1µm and the 128 x 128 FPA detector moves in a snake-like 
formation collecting one full spectral image of information at a time (see Figure 
4.5). The Agilent has more manual set-up tasks at the beginning of each 
session which includes focusing the light beam by ‘centerburst’ and verifying the 
energy. These are carried out within the spectrometer. 
 
 
Figure 4.5: Schematic representation of Agilent® detector snake-like 
movement 
 
4.4.1 High magnification infrared spectra 
All 67 specimens were analysed. Experiments were performed at the University 
of Exeter Physics Department on the Agilent Infrared spectrometer at high 
magnification. This is one of only a few high resolution spectrometers in the 
world currently and as such the experimental design evolved from a 
combination of recent unpublished work the team in Exeter had done before my 
arrival, and standard recognised infrared experimental protocol.  
A high magnification background takes approximately 20 minutes to acquire at 
a spectral resolution of 4 cm-1 with 256 scans, which is in total approximately 30 
minutes including set up time. A corresponding background was initially taken 
for every single sample, however it was soon realised that in some samples the 
large polyp specimen took up the whole surface area of the small CaF2 slide 
and as a consequence there was no space on the CaF2 slide free from paraffin 
or sample to take a background from. After a few experimental changes with 
background type and background: CaF2 sample ratio, it was decided that a 
separate blank CaF2 slide would be used and background performed every third 
sample to increase time efficiency. This seemed to give a reasonable signal to 
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noise ratio with good data. If more than three samples in a row were attempted 
then the signal to noise ratio would decrease and intensity map quality were 
noticeably poorer. The liquid nitrogen supplies were topped up before every 
background and subsequent sample analyses were performed. Measurements 
were therefore standardised as much as possible for temperature and light 
source average light intensity (maximum light intensity to integration time: part 
manual, part automated set up process for each new background). 
Experiments were conducted using the linear array detector of the Agilent 620 
FTIR microscope coupled to 670 Agilent Spectrometer in transmission mode 
using a pixel resolution of 1.1 µm and a spectral resolution of 4 cm-1. 64 scans 
per pixel were performed for the samples. Spectral information was acquired 
from mapping in a raster movement across 3x3 tiles. 128x128 pixels make up 
one tile and the data for each is acquired simultaneously. Each pixel is 1.1 µm 
in diameter, so a tile is 140 µm diameter; therefore each area of colon mapped 
was (3x140) 420 µm x 420 µm in diameter. Because data for each tile is 
acquired simultaneously, the time taken for a map of this size is much quicker 
than for standard resolution previously acquired on the PE system; however the 
overall mapped area is generally smaller (depending on area chosen). In most 
samples 3x3 tile size map enabled information to be gathered on one or two 
colonic glands only. A 3x3 tile takes approximately 45 minutes to map. 
Therefore each cycle of background to 3 sample slides took a minimum of 2 
hours 45 minutes for spectral acquisition alone. 
All samples were processed once. On a few occasions it was clear that the 
signal to noise ratio of the spectra on the raw data was poor and therefore the 
samples were repeated according to protocol. 
 
4.5 Data Analysis 
The spectrometer generates an inferogram based on all the biochemical 
information from the sample analysed. The output of spectral mapping is known 
as a hyperspectral image or hypercube. These are both discussed in three 
dimensions; the X-Y plane gives the spatial dimension (wavenumber and 
intensity) and the Z “3rd dimension” which represents the complete spectrum per 
pixel, which reflects the chemical composition of the sample.(Romeo et al. 
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2008) There is a huge amount of unrefined information which needs to be 
analysed and processed to understand its significance. The huge volume of 
data can prove challenging to interpret qualitatively due to the subtle change in 
intensity and shift in peaks that might be noted. Thus the field of chemometric, 
multivariate statistical analysis, was developed with various models to analyse 
the data. 
MATLAB® computer programmes were used for all analysis. The hypercube for 
each sample is loaded into MATLAB® for data analysis, the scripts for which 
were written in-house by an expert in chemometrics.  
 
4.5.1 Spectral Pre-Processing 
The generated interferogram was automatically Fourier-transformed and a 
transmission spectrum and absorbance spectrum subsequently calculated: 
  
        
 
 
                    
 
A= Absorbance, T= Transmittance 
 
  
 = Ratio of radiant fluxes 
 
Absorbance data was vector normalised to remove differences in the spectra 
due to changes in measured absorbance due to sample thickness. Certain 
wavenumbers were excluded- those which were outside the fingerprint region, 
1800- 900cm-1. Outside of these wavenumbers the mean spectra were found to 
be very noisy and therefore not useful because of reduced signal-to-noise ratio. 
Following those steps, the wavenumber area under the largest peak (1600- 
1700 cm-1) was used to visualise each image in an Intensity Map. The first pre-
processing step was to select the specific spectra from only the epithelium as 
area of interest as these spectra were predicted to be the most discriminatory 
when compared across groups. The raw data of each sample was uploaded 
into MATLAB® and epithelium selected from the intensity map following the pre-
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processing steps. The epithelial spectra were then selectively saved and used 
for comparative analysis, an example of which is shown in Figure 4.6 below. All 
other spectra were discarded from analysis. 
Regions of interest were then exported for chemometric analysis. 
 
 
 
Figure 4.6: (Above) White light image of a cluster of normal glands with 
corresponding intensity map of the same region (Below). In this example 
the epithelium can be clearly identified 
 
A paraffin correction was developed and built into the MATLAB® scripts to 
counteract the influence the paraffin peak had on the chemometric analysis. 
This was essentially used to negate the presence of paraffin in the mean 
spectra and to reduce the effect the paraffin would have on separating out the 
groups by principal component analysis. This was based on an Extended 
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Multiplicative Signal Correction (EMSC) to reduce variation in the paraffin 
signal, as described by Nallala et al.(Nallala et al. 2013)  
 
4.5.2 Chemometric Analysis 
Principal Component Analysis (PCA) is an unsupervised technique first applied 
to reduce data size by finding the largest variance within the dataset. It is a 
transformational tool used to make a predictive model based on multivariate 
analyses and assumes no prior knowledge about the dataset. It can reveal the 
data as a description based on variance as a set of co-ordinates in a data 
space. The analysis generates principal components, (PC) ‘1’ being the largest 
measure of variance, PC2 the next greatest variance and so on. The further 
down the list of PCs the greater the probability that it is just noise rather than 
real spectral differences that they describe. Only the first few components are 
used to produce a multi-dimensional figure representative of the transformed 
data (so the figure demonstrates the first few PCs of greatest significance). The 
maximum number of PCs is either the number of rows (spectra) or the number 
of columns (wavenumbers) in the data set, whichever is smaller.  
Analysis Of Variance (ANOVA) is then applied to find which PCs demonstrate 
the greatest significance in difference between groups i.e. PCA scores and use 
the most discriminative ones. 
Linear Discriminant Analysis (LDA) then uses the selected PCs and Gold 
Standard pathology information to train the classification model by maximising 
the separation between the groups and reducing variance within groups using a 
linear function. This is a supervised classification technique. 
Ideally the final step is to independently ‘test’ the classification model developed 
in the steps described above with new tissue samples, to see if the model can 
correctly identify the tissue samples. However, due to limited resources (time 
and financial) the final step to test the model was with a Leave One Sample Out 
Cross Validation (LOSOCV) method. This effectively tests the model with a full 
set of independent or brand new patients. All of the data from a single test set is 
removed from the model and the rest of the data is then re-run to generate the 
training set. The test sample is then predicted by the model to determine 
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accuracy. This is repeated with each sample being left out in turn (not 
necessarily leaving out a single patient as a few cases may have come from a 
single patient in the pathology group) and a contingency table generated which 
demonstrates the sensitivity (true positives correctly identified) and specificity 
(true negatives correctly identified) of the method.   
 
4.5.3 Peak Assignments 
Spectral peak assignments are determined in order to identify significant 
biochemical differences between different tissue types. Spectral peaks can be 
identified with regards to their specific biochemical properties and is carried out 
using previously published data. There is often significant overlap between 
peaks and so true identification of the biochemistry of a sample can be 
complex. Recent peak assignments, described by Movasaghi et al,(Movasaghi 
et al. 2008) were used for the experimental classification, details of which will be 
discussed further in chapter 5.  
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CHAPTER 5 
RESULTS 
 
All data from the 67 cases analysed were transferred from Exeter to be 
processed in Gloucester using MATLAB software with in-house tailored 
programming. In total over 2 million spectra for all groups were generated for 
analysis. 
Two cases were immediately excluded from the analysis (in the dysplastic and 
polyp cancer groups) because the data was corrupted and was unable to load 
in MATLAB and therefore unusable. This gave a total of 65 samples for 
analysis, see Table 5.1. 
 
 
Group Normal Dysplasia Cancer Polyp 
cancer 
Epithelial 
misplacement 
Sample 
Total 
15 15 8 12 15 
Table 5.1: Actual sample numbers per group 
 
The spectral data for all samples were loaded as a hypercube into MATLAB and 
data pre-processing applied as discussed in Chapter 4.  
The intensity map (of 1600-1700 cm-1 specifically) was compared to the 
corresponding white light image and the H&E to identify the detail of the sample 
areas and particular spectra in areas of interest could subsequently be manually 
selected.  
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5.1 Review of Spectral Quality 
The selected spectra representative of the epithelial area for each sample were 
separated into the five pathological groups.  The mean spectra for all samples 
within each group were then plotted on a graph together, offset for clarity.  
 
Figure 5.1: Mean spectra offset for all groups plotted with standard 
deviation.  
Green= Normal, Blue= Dysplasia, Red= Cancer, Orange= Polyp Cancer, 
Purple= Epithelial Misplacement 
 
The standard deviation (SD) +- 2 of the mean spectra per sample was 
calculated for each group (see Figures 5.2-5.6). 
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Figure 5.2: Mean spectra with SD for all cases plotted together for Normal group 
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Figure 5.3: Mean spectra with SD for all cases plotted together for Dysplasia group 
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Figure 5.4: Mean spectra with SD for all cases plotted together for Cancer group 
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Figure 5.5: Mean spectra with SD for all cases plotted together for Polyp Cancer group 
Page | 82 
 
 
 
Figure 5.6: Mean spectra with SD for all cases plotted together for Epithelial Misplacement group 
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Manual assessment was made of the quality of the mean spectra per sample 
and five samples were identified as having an unusually wide SD (out-of-
keeping with the rest of their group). These cases correlated with experimental 
difficulties that had been recorded at the time of experimentation: 
 On three samples taken on the same day, B2_1, C1, E1 an annotation 
had been written “poor quality, high noise to signal ratio, obvious 
problems”. Shortly after the Agilent technician visited Exeter to fine tune 
the Agilent Spectrometer. 
 On sample B3_1 an annotation had been written “air conditioning broken 
in room” and was the last sample of the day. These factors coupled 
together was a valid reason to assume that the overall temperature had 
warmed up and therefore affected the quality of spectral data in the last 
sample 
 On sample D14 an annotation had been written “problem with 
background. Had to use previous” so it would have been the fourth 
sample for the one background which may have affected the quality of 
spectral data 
Following manual exclusion of cases the mean and SD were then re-plotted for 
each group (See Appendix A, Figures 1.1-1.4; no exclusions were made from 
the Normal group so this was not re-plotted). 
It was decided that there was therefore adequate justification for an automated 
process to identify samples with poor quality spectra and replicate the manual 
process without adding any selection bias. This would enable poor quality mean 
spectra to be extracted from the dataset, but accepted that this might also 
exclude some that had not been identified manually and might therefore have 
been of ‘acceptable’ quality. Optimal values were chosen empirically to balance 
extraction of poor spectra without risk of reducing total case number too much 
by extracting reasonable spectra, and the following was set for all; sample 
exclusion made if the SD threshold is greater than 0.006 of 2 x SDs for greater 
than 60% of all selected wavenumbers. 
This selection method excluded the following samples; B2-1, B3_1, D14 and E1 
which was in-keeping with those that had been identified as part of the manual 
selection process, although not all. These 4 samples were then excluded from 
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any further analysis. The mean spectra with SD were then re-plotted (see 
Figures 5.7-5.10). Again no exclusions were made from the Normal group so 
that remains unchanged from the first graph plotted (Figure 5.2). 
The total number of spectra for all groups was 1,706,027. The group totals 
following epithelial selection and then extraction of poor quality spectra were as 
follows see Table 5.2. 
 
GROUP TOTAL SPECTRA 
Normal 178,166 
Dysplasia 479,595 
Cancer 341,445 
Polyp Cancer 306,381 
Epithelial Misplacement 400,440 
Table 5.2: Total number of spectra per group  
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Figure 5.7: Mean spectra for all cases plotted together for Dysplasia group post automated exclusion 
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Figure 5.8: Mean spectra for all cases plotted together for Cancer group post automated exclusion 
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Figure 5.9: Mean spectra for all cases plotted together for Polyp Cancer group post automated exclusion 
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Figure 5.10: Mean spectra for all cases plotted together for Epithelial Misplacement group post automated exclusion 
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5.2 Univariate Analysis 
Figure 5.11 shows the mean spectra as previously described in Figure 5.1, 
however values of the infrared peaks that demonstrate change between 
pathology groups have been identified and annotated. These correspond to the 
specific molecular biochemistry present in the tissues. 
 
Figure 5.11: Mean spectra offset for all groups plotted with standard 
deviation and peak assignments labelled.  
Green= Normal, Blue= Dysplasia, Red= Cancer, Orange= Polyp Cancer, 
Purple= Epithelial Misplacement 
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Table 5.3 demonstrates possible bonds responsible for these peaks.(Movasaghi 
et al. 2008) This is well corroborated by biochemical standards assigned 
courtesy of in-house Biophotonic records.  
 
 
IR Peak 
(cm-1) 
Nearest 
quoted 
(cm-1) 
Assigned Bond Tissue/substance Author 
1082 1082 νPO2- Symmetric band of the normal cells 
Phosphate band 
Collagen 
Oral Tissue 
Colon 
Lymphoid tissue 
(Fukuyama et 
al. 1999) 
(Rigas et al. 
1990) 
(Andrus and 
Strickland 
1998) 
1239 1238/39 PO2- Asymmetric stretching of nucleic acids & 
phospholipid 
Amide III 
Triglyceride 
Oral tissue (Fukuyama et 
al. 1999) 
1379 1380 δCH3 of lipid, protein, triglyceride 
C-O Stretching 
 C-H Deformation 
 N-H deformation 
Prostate, Colon 
Brain 
 
 
(Paluszkiewicz 
and Kwiatek 
2001; Richter 
et al. 2002) 
(Dovbeshko et 
al. 1997) 
1483 1482/3/5 C8-H coupled with a ring vibration of guanine Brain  (Dovbeshko et 
al. 1997) 
1544 1544 Amide II bands C-N stretching 
& CHN bending vibrations 
Fibroblasts (Wood et al. 
1996; Huleihel 
et al. 2002) 
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1652 1652 Amide I Cervix (Mordechai et 
al. 2004) 
1653 1653/4 C2==O cytosine 
C==O, C==N, N-H adenine, thymine, guanine, 
cytosine (DNA) 
 
Brain 
‘Tumour cells’ 
 
 
(Dovbeshko et 
al. 1997) 
(Dovbeshko et 
al. 2002) 
1654 As above    
1655 1655 Amide I (α-helix protein conformation) 
Amide I (ν C==O, δ C-N, δN-H)  
C==O cytosine 
C==O, C==N, N-H of adenine, thymine, 
guanine, cytosine 
Peak of nucleic acids due to the base carbonyl 
stretching and ring breathing mode 
Amide I has some overlapping with the 
carbonyl stretching modes of nucleic acid 
 Brain, Prostate 
Brain 
‘Tumour cells’ 
Brain 
 
Cervix 
 
Cervix 
 
(Yoshida et al. 
1997; 
Paluszkiewicz 
and Kwiatek 
2001) 
(Dovbeshko et 
al. 1997) 
(Dovbeshko et 
al. 2002) 
(Dovbeshko et 
al. 1997) 
 
(Chiriboga et 
al. 1998) 
 
(Fung et al. 
1996) 
Table 5.3: Peak assignments from the literature 
 
5.2.1 Derivative Spectra (Second Order) 
Derivation is used to eliminate random fluctuations in the baseline (first 
derivative) and slope (second derivative) of the absorption spectra. Calculating 
derivative of a mean spectrum is a method of identifying peak frequencies of 
biochemical components and therefore provides qualitative and quantitative 
information. It also causes effective narrowing of spectral features, which may 
enhance specificity of the method.  
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Representative spectra of the five pathology groups in absorbance units and in 
first and second derivative are shown in Figures 5.12-5.16 were calculated 
using an in-house MATLAB® programme. The peak assignments have again 
been annotated on each group, the positive peaks demonstrating the exact 
wavenumber of maximum absorbance of the peak. No particular shifts in 
frequency (>10 wavenumbers) were observed over the entire region (1800-
900cm-1) in any of the groups. The comparison of group spectra showed 
several differences in the peaks present, all 2nd derivative spectra are multiplied 
by -1 for the Figures. 
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Figure 5.12: Normal group derivatives; (Top) Mean spectra, (Middle) 1st 
order derivative, and (Bottom) 2nd order derivative for Normal group 
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Figure 5.13: Dysplasia group derivatives; (Top) Mean spectra, (Middle) 1st 
order derivative, and (Bottom) 2nd order derivative for Dysplasia group 
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Figure 5.14: Cancer group derivatives; (Top) Mean spectra, (Middle) 1st 
order derivative, and (Bottom) 2nd order derivative for Cancer group 
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Figure 5.15: Polyp Cancer group derivatives; (Top) Mean spectra, (Middle) 
1st order derivative, and (Bottom) 2nd order derivative for Polyp Cancer 
group 
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Figure 5.16: Epithelial Misplacement (EM) group derivatives; (Top) Mean 
spectra, (Middle) 1st order derivative, and (Bottom) 2nd order derivative for 
EM group 
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PO2
- modes of nucleic acids and carbohydrates at 1080 cm-1 contribute to the 
infrared spectra and are observed in greatest intensity in normal tissue, 
although there is not much difference seen across the entire dataset, it 
characterises the C-O bending mode of carbohydrate (see Table 5.4). One 
group has suggested that this peak is also due to the heterogeneity of mucous 
present, and in particular of crypt mucus.(Krafft et al. 2008) It has also been 
attributed to DNA. Phosphate bands of phospholipid have also been found 
between 1080- 1230 cm-1. 
The peak at 1128 cm-1 is of greater intensity in normal and dysplastic tissue in 
comparison with the other groups. It has been assigned to mucin at 1121 cm-1, 
with reduced concentration in diseased tissue because carcinogenesis cuts 
down mucus formation,(Conti et al. 2008) which would be in keeping with a 
much stronger peak observed in the normal and dysplastic groups. A lack of 
intensity in the EM group, as could be expected, could be because the 
internalised epithelium is not producing mucin to ‘normal’ levels seen on surface 
epithelium. This peak has also been attributed to RNA in normal tissue.(Argov 
et al. 2002) 
A peak at 1171 cm-1 is observed in the EM group and not so in the other four. 
This is likely due to C-O stretching(Rigas et al. 1990) and may be due to a 
change in protein conformation secondary to a reaction to its submucosal 
environment.  
The asymmetric PO2
- stretching of nucleic acid exists at 1240 cm-1 can be 
attributed to collagen in connective tissue,(Conti et al. 2008) specifically of the 
submucosa,(Krafft et al. 2008) or to the phosphate group of DNA.(Krafft et al. 
2008) The presence of this peak across all groups could indicate that as well as 
identification of epithelium, some submucosa was also involved, which would be 
particularly relevant in the invasive Cancer and EM groups given their glandular 
placement in the submucosa. This has also been attributed to an Amide III band 
in this position from C-N stretching and N-H bending. (Gasparri and Muzio 
2003) 
Symmetrical CH2 deformation modes at 1400 cm
-1 and asymmetrical CH3 at 
1460 cm-1 were presumed to be due to hypomethylation in cancer molecular 
structural change during carcinogenesis(Conti et al. 2008) or lipid contribution. It 
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is observed in the Dysplasia and EM groups (1401 cm-1 nearest reference 
peak), in keeping with Argov et al. who demonstrated various higher peaks in 
the Dysplasia groups and found that it correlated with grade of dysplasia.(Argov 
et al. 2002) 
The most distinctive peaks in the IR absorption spectra are assigned to the 
absorption of proteins: and this can be seen even in the raw spectral data. 
Amide I and II peaks found across all groups from 1513 cm-1 to 1685 cm-1 (Li et 
al. 2005; Krafft et al. 2008; Wood et al. 2011) vary in nature; the whole region 
demonstrates change in breadth of peaks and shoulder region varies.  
The most intense is the peak of Amide I found at 1655 cm-1 which corresponds 
to the C=O stretching with N-H bending and C-H of peptide bonds.(Ami et al. 
2003) This derives from a α-helix conformation, which could arise from a 
change in the secondary structure of proteins during carcinogenesis.(Conti et al. 
2008)  The specific peak of Amide I at 1637 cm-1 is attributed to epithelial 
peptide groups, and potentially polyglycosylated peptides in normal 
mucus.(Krafft et al. 2008)  It has been reported that the shape of this Amide I 
band is influenced by the secondary structure of proteins; α helices, β pleated 
sheets and other formations.(Lui et al. 2001) 
A prominent Amide II band at 1546 cm-1 arises from C-H-N and C-N stretching 
of peptide bonds in different vibrational modes.(Gasparri and Muzio 2003)  
 
5.2.2 Difference Spectra 
Difference spectra allow the best comparison to be made between groups, 
where otherwise only very subtle differences in peak height and intensity might 
be present. This method of analysis allows emphasise to be placed on spectral 
variation and to extract differences from one group to the next.  The initial peak 
assignments for raw mean spectra in all five pathological groups were the same 
across the groups except for 1650 cm-1 peak which demonstrated subtle change 
in peak height (wavenumber shift by only one or two).  
Difference spectra highlights the net difference between the sample and 
reference state spectrum, without distortion of peak heights, widths or noise 
levels, which simplifies data interpretation. The method does not however 
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overcome the difficulty of assigning relative importance to changes in spectral 
bands. Rather, the magnitude of the changes in the sample spectrum relative to 
the reference spectrum is used to drive data evaluation and 
interpretation.(Vrettos et al. 2006)  
The difference spectrum were calculated using an in-house MATLAB 
programme by subtracting mean normalized spectrum from one group from the 
same for another group. Figures 5.17- 5.20 show the resulting difference 
spectra obtained from taking the difference between mean normalised spectra 
from each group in turn against the Cancer reference group. The positive peaks 
in each plot represent biochemical constituents in abundance in the Cancer 
group, in contrast the negative peaks which represent lower concentration in the 
opposing Group. The noisy regions are removed from interpretation, and only 
the wide peaks are labelled and considered for description of the net group 
differences, with analysis based on the description of their size and position. 
 
 
 Figure 5.17: Cancer vs. Normal difference spectra 
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The comparison between Cancer and Normal groups in Figure 5.17 
demonstrates the strongest peak at 1587 cm-1 most significant in the positive 
region, so in the Cancer group. This is in keeping with the previous derivative 
findings that the protein Amide I and II change in intensity, probably due to 
change in structure, in the carcinogenesis process. That peak is situated in a 
wide band of noise from 1300-1800 cm-1 which doesn’t provide other useful 
information for those wavenumbers because the peaks are so sharp. This will 
have some paraffin contribution also complicating that section. Peaks at 1098 
cm-1 and 1217 cm-1 attributed to nucleic acids and fatty acids are greater in 
cancer compared with normal whereas short broad DNA peaks at 1030, 1060 
cm-1 along with RNA at 1127 cm-1 are stronger in the normal group. 
 
 
Figure 5.18: Cancer vs. Dysplasia difference spectra 
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 Figure 5.19: Cancer vs. Epithelial Misplacement difference spectra 
 
Figures 5.18-5.19 also demonstrate noise in the region of 1300-1800 cm-1 with 
very limited useful peaks, however, it appears that an intense, broad peak at 
approximately 1600 cm-1 appears to be most significant in the Cancer group 
compared to every other group, equally fatty acids at 1235 cm-1 and DNA at 
1371 cm-1. Although smaller peaks are most significant in the cancer group 
compared with all others. Glycogen at 1040 cm-1 is significant in cancer 
compared to all other groups except for normal, where the peak is not 
prominent, which would be in keeping with a modified glycogen and energy 
storage facility in carcinogenesis (the cancer process should be using energy 
stores). 
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 Figure 5.20: Cancer vs. Polyp Cancer difference spectra 
  
Peak differences between Cancer and Polyp Cancer groups show the least 
differences in overall intensity demonstrated. Although there are differences 
present between the two, they might indeed be very small and subtle, as would 
be expected. It could also be argued that the 1588 cm-1 peak is also very noisy, 
and therefore not reliably useful as a peak of significance to differentiate 
between the two groups. 
 
5.3 Bivariate Analysis 
Peak intensity ratio calculations are performed to better evaluate the 
biomolecular changes present between different groups. They reflect the ratios 
of protein, nucleic acid (NA) and fat content of the cells present and therefore 
give an indication of the carcinogenesis process, see Table 5.4. This has been 
used by many groups to demonstrate their findings.(Rigas et al. 1990; Li et al. 
2005; Zwielly et al. 2010) In this case the sum of the peak area of interest was 
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used (instead of the intensity at the exact wavenumber) using inverse 2nd 
derivative mean spectra. 
 
 
Group Peak Area 
Ratio 
NA: Protein 
(1038-1112:1610-1692) 
NA: Lipid 
(1038-1112:1375-1383) 
Normal 0.069 0.318 
Cancer 0.106 0.500 
Dysplasia 0.09 0.467 
Polyp Ca 0.093 0.484 
EM 0.065 0.366 
 
Table 5.4: Sum of peak area ratios for Group comparisons 
*NA= nucleic acids 
 
It is to be expected that during the process of carcinogenesis the cell lipid 
content is low because the energy is being used up for protein synthesis. 
Nucleic acids are large polyatomic molecules which include DNA and RNA 
made from nucleotides. Each nucleotide is made from a 5-carbon sugar, a 
phosphate group and a nitrogenous base. The sugar can be either oxyribose or 
deoxyribose according to its destination for RNA/ DNA. Therefore nucleic acid 
content should be associated with high protein production and lipid consumption 
with active carcinogenesis.(Isabelle et al. 2008; Wood et al. 2011)  
The NA:Lipid peak ratio is highest in Cancer, Polyp Cancer and Dysplasia 
groups. This corresponds with highest ratio scores for NA:Protein content in 
Cancer and Polyp Cancer relative to Normal and EM, which also correlates with 
discriminatory peaks described earlier. It should be expected that Normal and 
EM would be of similar value, the fact that cancers are found to be different 
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would assist in the clinical scenario discriminating either from cancer. The 
greatest discrimination appears to be provided by the NA:Protein ratio which 
may therefore be useful to help separate the EM Group from the other groups. 
Interestingly the Dysplasia group is mid-table for both ratio comparisons which 
would be in keeping with the progressive change in cellular biochemistry from 
normal to malignant and associated biochemical changes described, although 
Argov et al. found highest peak ratios for NA and lipid overall in their dysplastic 
groups.(Argov et al. 2002)  
The ratios used here are calculated from the mean spectra with overlapping 
standard deviations therefore further work would be needed to be able to 
produce individual error bars for these values and confirm the results found. 
 
5.4 Multivariate Spectral Analysis 
Univariate and bivariate analysis techniques are useful in analysis of individual 
peaks and to analyse the differences between groups in descriptive terms, 
however as previously discussed, there is considerable overlapping of peaks 
and band assignments which makes the techniques less favourable than using 
multivariate analysis to really tease out the differences and assess the 
importance given to the differences between the groups. For these reasons it 
was important to implement a combination of both supervised and unsupervised 
multivariate techniques to construct a classification model based on variance 
observed between the spectra. The use of Principal Component Analysis 
(PCA), an unsupervised method, then Linear Discriminate Analysis (LDA), a 
supervised method, is well described in the literature. Leave One Sample Out 
Cross Validation (LOSOCV) was then subsequently used to probe the 
performance of the classification model. The LOSOCV is employed as a robust 
test for the model.  From this, sensitivity, specificity and overall performance 
could be determined. 
In this analysis a ‘Four Group’ and a ‘Two Group’ model were performed and 
these will be discussed at length in the following sections. At this point a note 
should be made about the Polyp Cancer and Cancer groups. It was found that 
the Difference and first and second Derivative spectra for these two groups 
demonstrated a high degree of overlap (see Figure 5.15 and 5.19), and it was 
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difficult to separate them out on the basis of the early analysis of the spectral 
biochemical information. This mirrors our biochemical understanding that there 
should be a high degree of overlap between early polyp cancer and advanced 
cancer, because there is little biochemical difference between the two except for 
that of histological Grade (variable low-high). Any differences demonstrated 
between the two may be due to ‘invasiveness’ since that is the only discernible 
difference between the two, an unidentified molecule such as a protein may be 
found in higher quantity in the Cancer group because it is invading through the 
submucosa to a varying degree away from its position on the epithelial surface, 
whereas Polyp Cancer group may be lacking in this because it has not 
demonstrated any invasion through the submucosa. To assess whether there 
was truly only a very small difference between the two, PCA-fed LDA analysis 
was performed of the Polyp Cancer and Cancer groups in comparison to the 
Normal group, to assess the expectation that it would be difficult to separate the 
two cancer groups against the normal spectra and validate the combination of 
the two groups. 
PCA-LDA for the cancers against normal spectra demonstrated that the 
specificity of the model to separate normal from cancer is higher (88%) than the 
specificity to discriminate Cancer from polyp cancer (76%). These results justify 
the combination of the two cancer groups together for analysis as one 
(therefore increasing the group size by default and increasing the spectral 
information for the model). 
 
5.4.1 ‘Four Group’ Model 
The Four Group Model dataset consists of individual spectra from Normal, 
Dysplasia, and Epithelial Misplacement groups and the Polyp Cancer and 
Cancer groups together as Combined Cancer, labelled ‘Abnormal group’ (a total 
of four groups all together) A comparison of the mean spectra between the four 
groups can be seen in Figure 5.21 with standard deviation plotted. The mean 
spectral data demonstrates several differences in the peaks between the four 
group means, particularly in the regions of 1080 and 1240, and 1550 and 
1650cm-1, as discussed previously. However there is overlap in the standard 
deviation of the group means, particularly noticeable at 1550 and 1650cm-1and 
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the trough of 1600cm-1, so there is some significant spread of the values at 
these points. Because the SD is based in the mean, the spread cannot be 
attributed to the whole group or one aberrant sample within the group. 
 
Figure 5.21: Graph demonstrating mean spectral differences in Four 
Group Model. Green = Normal group, Blue = Dysplasia group, Purple = 
Epithelial Misplacement group and Black = Abnormal combined cancer 
group with standard deviation plotted as shaded areas 
 
Page | 108 
 
To establish biochemical changes in the spectral dataset across the selected 
epithelial spectra selected, Principal Component Analysis (PCA) was used. 
PCA reduces the whole dataset to a few spectral components and reveals the 
maximum variance across the whole dataset. The PCA creates PC scores and 
loads in order of variance. Analysis of variance (ANOVA) was then performed 
on the PCs to identify the most significant PCs, a histogram of which can be 
seen in Figure 5.22 demonstrating the importance of each individual PC (of the 
top 25). In the Four Group Model, PCs 2, 3 and 4 (with significant contribution 
from PC1 and 6 too) were the top three most significant PCs. Throughout the 
experimental process there are many factors which could erroneously increase 
variation between the groups such as; 
 
 Paraffin signal despite good EMSC correction within the programme 
 Storage of slides- scratches from transport and dust and dirt from 
cardboard storage sleeves 
 Experimentation set-up variation 
 Instrument variation (light source)  
 Cell cycle variation within a pathological group 
 Environmental factors such as water and carbon dioxide vapour 
 Misclassification of glands during identification process 
 
These are all acknowledged and as much as possible corrected at the time so 
that the PCA scores can be relied upon to be a true measure of variation in 
tissue rather than anything else. However corruption by extraneous factors 
could still contribute to the separation, hence the need for a detailed review of 
each PC loading which thus aims to avoid the potential for any of them to be 
significant in calculation the variation across the dataset. 
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Figure 5.22: Histogram to show plot of Fratio vs. 25 Principal Components 
score  
 
A scatter plot was also created to demonstrate the maximal variance of the 
groups in three dimensions (3D); using the three most important PC selected 
plots (in this case 2, 3 and 4). It generates an image of how well the groups 
separate on the basis of three PCs in the context of 3D time and space 
separation, see Figure 5.23. The separation of the Four Group Model appeared 
good, with some overlap as expected but the majority of the groups being well 
circumscribed and distinct from each other. The Dysplasia group demonstrates 
the greatest inter-group variability with wide spread and the most outliers, 
probably because of the significant pathological variation within the group, 
ranging from near-normal to near cancer and all in between. This is to be 
expected considering that some glands will close to normal biochemically and 
some much more similar to a Cancer type.  
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Figure 5.23: PCA Scatter Plot (PC2 vs. PC3 vs. PC4) demonstrating 
maximal variance in Four Group Model. Green = Normal group, Blue = 
Dysplasia group, Purple = Epithelial Misplacement group and Black = 
Abnormal combined cancer group 
 
Figure 5.24 demonstrates the PC loadings for the most significant of the three 
principal components PC 2, 3 and 4 in detail: 
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Figure 5.24: PC loadings for PC 2, 3 and 4 with peak label assignments 
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Peak assignment labels have been added to these PC loadings (Figure 5.24). 
The most significant peaks in the 3 PCs are a recurrence of 1040, 1095, 1170, 
1240 and 1630cm-1 as discussed previously. 
These PCs were then used to develop the Linear Discriminate Analysis (LDA) 
models for the Four Group analysis. All 25 of the calculated PCs were used as 
input into an LDA classification to maximise the variance between pathological 
groups and reduce variance within groups. A two dimensional scatter plot of the 
linear discriminant (LD) scores for the dataset are displayed in Figures 5.25. 
Each dataset produced various combinations of LD subplots as a result of the 
LDA performed which have not been included in this thesis due to sheer volume 
of data, but have been examined as part of the analysis. 
The efficiency of the PCA-fed LDA classification model was then evaluated 
using leave one sample out cross validation (LOSOCV) described in Chapter 4. 
This method determines whether the predications of the classification model are 
accurate, is independent data (i.e. new case samples) is not available. The 
classification model was constructed with all 25 PCs and results reflect the 
number of spectra correctly classified for each group within the Four Group 
Model, see Table 5.5. 
 
 Spectral Classification 
Pathology Group Normal Dysplasia Combined 
Cancer 
EM 
Normal 85033 39384 36712 17037 
Dysplasia 93094 199827 161559 25115 
Combined Cancer 73969 110987 356515 106355 
EM 69107 29865 62893 238575 
Average Sensitivity (%) 48 41 55 60 
Average specificity (%) 85 85 75 89 
Table 5.5: Leave one sample out cross validation confusion matrix table 
with average sensitivity and specificity. EM= Epithelial Misplacement. 
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Figure 5.25: LDA Scatter Plot (LD1 vs. LD3) represents the clustering of 
pathological groups for the Four Group Model; each point represents a 
single spectra. Green= Normal group, Blue= Dysplasia group, Black= 
Abnormal group and Purple= Epithelial Misplacement group 
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These results show a high average specificity (75- 89%) but low average 
sensitivity (41- 60%) in comparison for the LOSOCV evaluation. This reflects a 
poor measure of PCA-fed LDA classification model performance. This large 
number of misclassified spectra may be due to unbalanced number of spectra 
in each group, significant differences in cell sample with variation in degree of 
maturation and cell cycle, problems with epithelial cell selection, inclusion of 
poor quality spectra, and inter-sample spectral variability within the groups. 
Ideally the number of spectra per group in the model should be equal for the 
LOSOCV procedure to avoid poor prediction results. It was decided to perform 
the whole process again with the same number of spectra in each group to see 
if this had a significant effect on results. 178,000 spectra (smallest group 
determines number which was the Normal group) were selected at random from 
each group and entered into the PCA-LDA model for LOSOCV. The results of 
which can be seen in Table 5.6: 
 
 Spectral Classification 
Pathology Group Normal Dysplasia Combined 
Cancer 
EM 
Average sensitivity (%) 55 41 55 61 
Average specificity (%) 85 86 78 89 
Table 5.6: Leave one sample cross validation sensitivity and specificity 
results for the revised Four Group Model using only 178000 spectra per 
group. EM= Epithelial Misplacement 
 
This normalisation for spectral number made a small improvement to 
classification of the Normal group but overall minimal significant improvement, 
therefore the poor classification model is probably explained by pathological 
variation and selection error, rather than group size.  
It was decided to further analyse the model performance by using the 
percentage of classified spectra in each specimen, rather than just the spectra 
alone out-of-context with the pathological classification. This was performed by 
classifying each case per group depending on majority spectral classification to 
give a ‘majority spectral vote’ per case. This was to better reflect the 
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classification per sample and remove the bias of outlying spectra which may 
have affected LOSOCV performance initially. The classification table is shown 
in Table 5.7. 
 
 Case classification by majority percentage 
Pathology Group Normal Dysplasia Combined 
Cancer 
EM 
Normal 11 2 2 0 
Dysplasia 2 9 1 1 
Combined Cancer 2 3 10 4 
EM 1 2 3 8 
Average Sensitivity (%) 73 69 53 57 
Average specificity (%) 89 85 86 89 
Table 5.7: A confusion matrix table based on classification of cases per 
group by majority percentage classified spectra, with average sensitivity 
and specificity. Correctly classified cases in bold. EM= Epithelial 
misplacement 
 
Table 5.7 demonstrates a much improved model performance when analysed 
on a percentage basis rather than for all spectra individually. Particularly 
sensitivity is much improved across the pathology groups, and prediction greatly 
improved (reading across the rows). In the normal group, only 2 were 
misclassified into dysplasia and combined cancer respectively, 4 samples out of 
the dysplasia group spread across the other groups. The cancers and EM 
cases were most frequently misclassified into each other’s group, which might 
be expected given that histologically these are the most difficult to distinguish 
from each other, and the differences therefore are very small for the model to 
use. The majority vote acknowledges that there may be significant number of 
misclassifications per sample but, if overall, the classified spectra put the 
sample in its true group then the model has performed well, hence the increase 
in performance. This probably reflects a true comparison with a pathologist 
discriminating between different pathology cases where there may be evidence 
of mixed glands present or uncertainty in difficult cases. 
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5.4.2 ‘Two Group’ Model 
The next step in the analysis of the spectra was to assess the use of 
multivariate analysis in the differentiation of EM and Cancer groups. As 
discussed in Chapter 1, this is an area of great clinical need (see Section 1.7.1) 
with great scope for the use of infrared analysis to differentiate cancer from non-
cancer as an additional complimentary tool to aid accurate and efficient 
diagnosis. 
 
The Two Group Model dataset consists of individual spectra from Combined 
Cancer (Polyp Cancer and Cancer groups together) labelled ‘Abnormal’ group 
and Epithelial Misplacement group. A comparison of the mean spectra between 
the two groups can be seen in Figure 5.26 with standard deviation (of the mean) 
plotted. It demonstrates several differences in the peaks between the two 
groups, particularly in the regions of 1080 and 1550 cm-1 as discussed 
previously, although overlap in the SD of the population means is also 
demonstrated making it difficult to assess their significance based on this alone. 
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Figure 5.26: Graph demonstrating mean spectral differences in Two Group 
Model. Purple= Epithelial Misplacement group and Black= Abnormal 
group with standard deviation plotted as shaded areas 
 
PCA was performed for the Two Group Model to determine the variance across 
the whole dataset. Again, the top 25 most significant PCs were determined, 
ordered and listed by ANOVA. Figure 5.27 demonstrates very clearly that there 
were three PCs, 2, 3 and 4, which were much more contributory than the others 
in the top 25 identified. 
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Figure 5.27: Histogram to show plot of Fratio vs. 25 Principal Component 
scores  
 
The three dimensional scatter plot (Figure 5.28) using PC 2, 3 and 4 
demonstrated a clear separation between the two groups, which although 
adjacent, shows two well described populations in separate clusters containing 
minimal outlying spectra, (given that every spectra is plotted), implying that the 
epithelial identification was strong in this selection of spectra with minimal inter-
group variability. All PC loadings were examined but Figure 5.30 demonstrates 
the most significant PC loadings, PC 2, 3 and 4, in more detail, with 
identification of major peak assignments, particularly repeating the theme of 
1080, 1230, 1580 and 1650 cm-1 as previously discussed. 
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Figure 5.28: PCA Scatter Plot (PC2 vs. PC3 vs. PC4) demonstrating 
maximal variance in Two Group Model. Purple= Epithelial Misplacement 
group and Black= Abnormal combined cancer group 
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Figure 5.29: PC loadings for PC 2, 3 and 4 with peak assignment labels 
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The PCs were then used to develop the LDA model for the Two Group analysis, 
and a LDA histogram representative of the group clustering produced, see 
Figure 5.30. This shows excellent group separation, with only very minimal 
overlapping at the base. This very clearly shows that the PCA-fed LDA model 
has been able to discriminate between the two pathology groups very 
effectively. 
 
 
Figure 5.30: LDA Histogram (LD1 vs. LD2) representing the clustering of 
the two groups in the Two Group Model; Purple= Epithelial Misplacement 
group and Black= Abnormal group 
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The efficiency of the PCA-fed LDA model was then evaluated using LOSOCV 
again, reflecting the number of spectra classified correctly within the Two Group 
Model. The results of this can be seen in Table 5.8. 
 
 Spectral Classification 
Pathology Group Combined Cancer EM 
Combined Cancer 533036 114790 
EM 101714 298726 
Table 5.8: Leave one sample out cross validation confusion matrix.  
EM= Epithelial Misplacement 
 
The LOSOCV results are excellent for the Two Group Model, with an average 
sensitivity of 75% and specificity of 82%. This classification model was therefore 
highly successful at identifying the true positives with few misclassifications. 
 
 Case Classification by percentage 
Pathology Group Combined Cancer EM 
Combined Cancer 16 3 
EM 3 11 
Table 5.9: A confusion matrix table based on classification of cases per 
group by majority percentage classified spectra. Correctly classified 
cases in bold. EM= Epithelial misplacement 
 
Again the PCA-fed LDA LOSOCV results were analysed by majority percentage 
on a per-case-basis per group as can be seen in Table 5.9. Again this has 
shown an overall improvement in the model performance with an increase in 
average sensitivity to 79% and specificity to 84%. This improvement is less 
dramatic than in the Four Group Model, because there were fewer 
misclassifications initially and the model was a higher performer. However it 
does demonstrate that analysing on the basis of percentage vote drives a 
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majority decision that is even more accurate for this Two Group classification 
model, an excellent result. 
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CHAPTER 6 
CONCLUSIONS 
 
The scope of this thesis was to evaluate the use of high resolution infrared 
spectroscopy in the analysis of colonic pathology. There is limited use of this 
novel technique in the literature, although much already at standard resolution 
for comparison. This research specifically investigated the role of high 
resolution infrared spectroscopic analysis in the differentiation of cancer from 
the benign pathological phenomenon of epithelial misplacement (EM), through 
the interrogation of the molecular structure of the various relevant pathological 
entities. There is conundrum in the diagnosis of epithelial misplacement and 
therefore huge potential for any novel analysis technique to have a positive 
impact in the diagnostic process in terms of speed and accuracy. Multivariate 
statistical methods, to extract the useful diagnostic information, were employed 
to discriminate normal colorectal epithelium from dysplastic and cancerous 
epithelium, as well as the discrimination of EM from cancer. Specifically 
principal component-fed linear discriminate analysis (PCA-fed LDA) was used 
to interrogate the experimental spectra and leave one sample out cross 
validation (LOSOCV) used to examine the robust quality of the classification. 
The high resolution technique took approximately 55 minutes per sample to 
collect a huge amount of raw data; each tile contained 128x128 pixels (64 
scans per pixel acquired), thus generated 1,048,576 scans per tile, a total of 
9,437,184 scans (for 3x3 tiles) for analysis per sample. The samples were 
prepared using formalin fixed paraffin embedded tissue as per routine clinical 
preparation with no extra processing steps required. This allows the technique 
to be applied for use in clinical diagnosis, given that it does not require any 
extra processing and is a fairly rapid technique. This makes it supremely 
suitable as a complimentary diagnostic technique for difficult cases. 
The high resolution spectra acquired from the Normal, Dysplasia, Cancer and 
EM pathologies demonstrated various differences in their biochemical 
constituents. Univariate and bivariate analysis described various changes in 
peak shapes, position and intensity throughout the fingerprint region of 1800- 
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900cm-1, corresponding to a change in proteins, Amide I II and III, nucleic acids, 
lipid and carbohydrate. There was a significant contribution from paraffin 
despite efforts to negate this in the data analysis methods applied. Overall DNA 
and Amide III peaks were more dominant in malignant cells, indicating 
increased cellular content, consistent with the current literature findings. The 
dysplasia group proved the most difficult to analyse as it spanned the breadth of 
findings and was really very varied. This was reflected in the PCA models, 
which detailed the spread with a wide- tailed scatter plot (see Figure 5.23). This 
probably reflected the inter-group pathological variability, ranging from close-to-
normal to close-to-cancer, and hence why it is in keeping with the expectation 
that dysplastic cells by the nature of their biochemistry are varied, and despite 
trying to reduce this by only using ‘low grade’ or ‘high grade’ can still show huge 
biochemical differences across the group.  
Various methods were introduced in order to optimise the PCA-fed LDA 
classification models, including application of standard deviation to filter outliers 
and normalising data, however the Four Group Model demonstrated a high 
average specificity (75- 89%) but low average sensitivity (41- 60%) following 
LOSOCV, which reflected a poor measure of PCA-fed LDA classification model 
performance. This was improved, although not dramatically, when the spectra 
were cut to 178,000 per group to reduce bias for unequal dataset. Other causes 
for the large number of misclassified spectra include problems with epithelial 
cell selection, inclusion of poor quality spectra, and inter-sample spectral 
variability within the groups. 
The Two Group Model (EM compared to combined cancers) however 
demonstrated overall a much better performance with an average sensitivity of 
75% and specificity of 82%. This model demonstrates a good ability to 
distinguish between the two pathology groups with accuracy and reliability. The 
improvement between the two Models may be because of the sheer numbers of 
spectra involved in the first model (over 1.5 million) may actually flood the 
model without being of use, there may be a saturation point which beyond, 
adding more spectra does not improve the discrimination model because 
population variance has been captured. The fact that the Four Group Model 
improved with spectral reduction is in keeping with this, and would certainly be 
an area to examine in more detail in the future. 
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Several other major factors were discovered which might influence the 
performance of the discrimination models based on the experimental design; 
Firstly the pathological methods must be scrutinised for weakness. All samples 
were analysed by two different consultants for the diagnosis, however only one 
identified the glands for the experimentation, and it was hard to identify the 
same gland in some cases, as the plane of examination changed with the 
changing depth of every section through the specimen. These glands were not 
always in the same stage of the cell cycle, or even the same orientation, 
therefore the spectral analysis may have been at varying depths in the crypts 
thus introducing variability in the genetic biochemistry (proliferation occurs at 
the base of crypts and differentiation variably higher up the crypts). Once the 
experiments were underway I again found it difficult to identify exactly the same 
glands that had been identified in the initial white light diagrams, and, despite 
the use of detailed topographical maps, sometimes it was simply impossible to 
identify the exact same ones which would have introduced further variability.  
There also appeared to be some evidence of a few times where normal glands 
were present amongst pathological glands (particularly in the Dysplasia group) 
and so this would have contributed to the variability. I would be keen to address 
this further with a detailed analysis of the spectra selected and compared with 
the classification model, and then go back to the pathologists to re-examine the 
slides. This would be difficult as some of the white light images were poor, and 
especially in the Cancer groups, were difficult to interpret. Figure 6.1 
demonstrates an intensity image of a cancer gland with little or no identifiable 
landmark and shows just how difficult epithelial selection was in some cases, 
compounded on occasion, by cautery artefact from the polypectomy procedure 
damaging tissue quality resulting in the loss of tissue landmarks, such as seems 
evident on this image. 
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Figure 6.1: (Above) The white light image for a cancer sample and (Below 
left): The corresponding intensity image with limited glandular landmark 
for epithelial selection, as seen on the right 
 
There were various problems with the instrumentation and set-up, compounded 
because the use of the high resolution technique is really still only early in its 
infancy. The study design was aided by work from the MiNERVA project (see 
Chapter 3), but often decisions made about set-up were being learnt as the 
experiments proceeded. For example, the number of acquisitions per sample 
was set at 64 (background 256) which was to keep the time per sample at a 
reasonable length. However increasing this would have improved spectral 
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quality and this should be investigated in the future. I would also change the 
background acquisition in future experiments. It was decided to perform a 
background every three specimens because there was not always enough clear 
room on each slide to take a measurement. However, it became clear that the 
spectrometer warmed significantly between the first and third specimen and so 
one background was not sufficient over this time. Ideally a background should 
be performed every single time so that variation in CO2, water and heat could 
have been made. I made this choice because of time and space on the slide 
pressures but in the future would most certainly change this aspect of data 
collection, including switching to bigger calcium fluoride slides if the polyp was 
large and more room was needed to give a clear area around it.  
Other causes of reduced signal to noise ratio included a centre-burst problem 
which caused the results to be affected in one tile per set. There was also no 
stage calibration on the spectrometer so I was unable to come back to the exact 
same image when interchanging swinging between white light and infrared and 
back again. 
There was initially a problem in calibration between white light and infrared, so 
much so that when the image had been identified in white light the infrared 
moved a whole tile ‘shot’ away, so this had to be taken into account when 
choosing a gland and definitely affected the quality of the gland selected and 
then the ability to come back at a later date and select the epithelium, because 
the white light and infrared image were completely misaligned. This was 
corrected by Agilent technicians but only after a significant number of 
experiments had already been conducted. 
I also became concerned with the quality of the transportation and movement of 
slides in the pathology cardboard trays to and from Exeter over the course of 
the experiments. It became obvious that fluff and debris from the cardboard 
trays were contaminating the slides. They were also getting scratched and 
showing considerable deterioration in condition of the slides. This would have 
caused increased scatter and artefact to be introduced into spectra and 
therefore reduced the overall quality of the spectra obtained. To combat this 
problem slides should be stored in a specific rigid plastic container to prevent 
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them knocking and moving during transport which would minimise the wear and 
tear over time. 
 
7.1 Future Work 
As well as making the changes suggested in experimental design as previously 
indicated, optimisation of the PCA-fed LDA classification model would be an 
important focus of future work to improve the accurate classification of colonic 
pathologies. Firstly selection of the spectra should be more tightly controlled. 
This should be investigated in a variety of ways but initially a case-specific 
selection would be implemented, by which the individual classification for each 
case would be analysed separately and only included if the values reached a 
certain percentage (for example, if a case had 20% Normal, 50% Dysplasia and 
30% EM classified spectra it would be classified overall as a dysplasia sample). 
Analysis of the Dysplasia group should be performed in much greater detail, 
potentially reducing the number of outlying spectra in the wide ‘tail’ on the 
scatter plot. The classified spectra could be plotted over the top of the original 
selected spectra on the intensity map and then outliers could be identified, 
areas where misclassification was performed by human error would be 
identified, and selection of spectra could be reassessed and hopefully 
improved. Further improvement of the models could be made by changing the 
number of principal components (PCs) used, more careful selection of PCs and 
more variation in the LDA. The standard deviation filter could be extended and 
moderated to exclude more of the outlying spectra too, which would improve the 
performance of the model. 
Finally the model should be tested with new samples rather than using the 
leave one sample out cross validation techniques. LOSOCV is an excellent 
alternative when there are no new samples, but to rigorously test the prediction 
model, new samples should be used which are completely unknown to it. This 
would give a completely unbiased and totally independent and more robust 
reflection of the performance of the model along with average sensitivity and 
specificity. 
In the future the number of specimens, with which to train the model and 
increase population variance, should be increased. This should also increase 
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the breadth of pathology, potentially to include other benign pathologies such as 
inflammatory bowel disease as these are areas of clinical need and would be 
complimentary to Raman spectroscopy use in the colorectum in real-time in 
difficult diagnostic areas. Larger spectral models are required to reflect the great 
variation expected to be encountered clinically. 
Other forms of chemometric analysis could also be explored, for example the 
use of artificial neural networks and cluster analysis to extend the predictive 
capacity and therefore usefulness of the model. These could be implemented 
also to analyse the spectral quality of these results and streamline the model 
further. 
Exploitation of other optical analysis techniques could be used as a 
complimentary technique for further biochemical analysis of colon cases. This 
would necessitate prospective data collection so that samples could be fresh 
frozen, for example for Raman spectroscopy, as well as paraffin embedded for 
the infrared spectroscopy, but this would generate a great deal more scope in 
data analysis across the dataset. 
 
Overall, this study has demonstrated the use of high resolution infrared 
spectroscopy as a complimentary diagnostic tool in colonic pathology analysis, 
with its specific potential use in the differentiation of epithelial misplacement 
from cancer. This is an area where early detection and diagnosis is key, both to 
ongoing patient management and the time taken to diagnosis, which is 
extremely important in current NHS practice. (NHS Interim Management and 
Support 2014) There is still much work before it can be clinically implemented, 
including a large multicentre trial to evaluate its use further. High resolution 
spectroscopy is certainly an exciting area of optical analysis and one in which 
routinely processed samples can now be analysed and yield a huge amount 
more data than ever before with standard infrared spectroscopy, thus increasing 
its clinical and commercial potential in line with that of Raman techniques and 
the in-vivo real time analysis of samples. The next step in the use of high 
resolution techniques will have to deal with the huge volume of data and 
computer analysis, and be responsive to the risk that an experiment might 
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potentially generate more data than is actually useful or can be analysed 
adequately.  
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APPENDIX A 
 
Mean Spectra for all groups (except Normal group which remained unchanged) 
following manual exclusion of spectra. 
 
Figure 1.1: Mean spectra for all cases plotted together for Dysplasia group 
post manual exclusion 
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Figure 1.2: Mean spectra for all cases plotted together for Cancer group post 
manual exclusion 
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Figure 1.3: Mean spectra for all cases plotted together for Polyp Cancer group 
post manual exclusion 
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Figure 1.4: Mean spectra for EM group post manual exclusion 
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